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ABSTRACT 
Oxidative stress and tissue remodeling are involved in the development of fibrosis of the 
lung and heart. Extracellular superoxide dismutase (EC-SOD) is an important antioxidant 
enzyme that has been shown to limit inflammation and fibrosis. Idiopathic pulmonary fibrosis is 
a lung disease characterized by severe, progressive interstitial fibrosis. Cardiac fibrosis has 
various causes but is a fatal side effect of treatment with the chemotherapeutic doxorubicin. Both 
of these diseases involve oxidant/antioxidant imbalances and can be studied through animal 
models. It was hypothesized that one mechanism through which EC-SOD protects the lungs 
and heart from inflammation and fibrosis is by preventing oxidative shedding of extracellular 
matrix components, specifically syndecans.  
In the lung, wild type and EC-SOD KO mice were treated with titanium dioxide, 
asbestos, or Bleomycin. Over the course of injury, EC-SOD KO mice have significantly higher 
levels of shed syndecan-1 and -4 in their bronchoalveolar lavage fluid and tissue. By IHC 
staining, the lung distribution of EC-SOD decreases in areas of fibrosis while syndecan-1 
increases. Furthermore, in vitro, EC-SOD prevents syndecan-1 shedding from epithelial cells 
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through its antioxidant activity and by directly binding to syndecan-1. Shed syndecan-1 is 
chemotactic to neutrophils and inhibits wound healing. In the heart, the signifiance of EC-SOD 
on normal heart morphology, fibrosis, and cardiac function were evaluated in wild type and EC-
SOD KO mice in a doxorubicin-induced LV fibrosis model. The lack of EC-SOD causes LV 
posterior wall thinning and ventricular dilation without an insult. After an oxidative insult 
induced by doxorubicin, EC-SOD KO mice lost significantly more cardiac function compared to 
wild-type mice, had enhanced inflammatory cell recruitment, increased shedding of syndecan-1 
from the heart and increased caspase-3 activation or apoptosis.  
In summary, this study shows that EC-SOD is important in the maintenance of normal 
cardiac morphology, the development of cardiac fibrosis, inflammation, apoptosis, and the loss 
of function associated with oxidative cardiac injury. In the lung, this investigation shows that the 
loss of pulmonary EC-SOD leaves syndecan-1 vulnerable to oxidative stress and that oxidant-
induced loss of cell surface syndecan-1 impairs re-epithelialization, induces inflammation, and 
promotes a fibrotic microenvironment in the lung.  
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1.0  INTRODUCTION 
Tissue remodeling and the development of fibrosis are reparative responses to injury and 
destruction of the pre-existing tissue structure. The body attempts to replace damaged cells and 
extracellular matrix, most commonly via the deposition of matrix components such as collagen 
and fibrin. The reversibility of fibrosis is under constant debate and differs by organ. In the lung 
and heart, chronic inflammation or injury and abnormal healing of residential cells can lead to 
fibrosis development. In order to move toward therapeutic options for pulmonary and cardiac 
fibrosis, a better understanding of the processes and mechanisms involved in fibrogenesis is 
required. Recent studies support a role for oxidative stress and antioxidant imbalances in the 
pathogenesis of both of these conditions. 
1.1 IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic Pulmonary Fibrosis (IPF) is a detrimental interstitial lung disease characterized by 
severe and progressive fibrosis of the alveolar interstitium. In the United States, the prevalence 
of IPF is estimated to be 42.7 per 100,000 and the disease incidence to be 16.3 per 100,0001. 
Patients develop symptoms of dyspnea (shortness of breath) and non-productive cough with 
presentation between 50-70 years old. IPF is slightly more common in males than females2 and 
has a dismal prognosis with a 5-year mortality rate between 50-70%3, 4. 
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1.1.1 Pathophysiology 
Pulmonary fibrosis can occur in various situations: due to an unknown stimuli (idiopathic); 
environmental/occupational exposure i.e. asbestos, silica; induced by pharmacological agents i.e. 
Bleomycin; radiation expsorure and associated with other primary diseases such as scleroderma 
or familial forms2, 3. While the pathogenesis of IPF remains unclear, inflammation and 
oxidant/antioxidant imbalances within the lung are believed to be involved5, 6. Evaluation of 
bronchoalveolar lavage fluid (BALF) samples reveals increases in neutrophils, mild increases in 
eosinophils, and overall increases in cell counts3. Increases in BALF neutrophils and eosinophils 
suggest an increase likelihood of disease progression and lack of response to immunosuppressive 
agents4, 7, 8. In IPF, these inflammatory cells may release exaggerated amounts of reactive oxygen 
species9. Studies show increased reactive oxygen species production in leukocytes from the 
serum and evidence of enhanced oxidative stress in plasma and BALF of IPF patients 10, 11. 
Levels of oxidative stress have been shown to negatively correlate with aspects of pulmonary 
function in IPF patients and may provide information about disease severity5.   
 
1.1.2 Diagnosis and Pathological Findings 
From the time of IPF diagnosis, there is a mean survival of 3-5 years3, 4. A diagnosis of IPF is 
made from a thorough history and physical, chest radiography, pulmonary function tests, high 
resolution computed tomography (CT), and lung biopsy.  In the presence of a surgical biopsy 
showing a histological pattern of Usual Interstitial Pneumonia (UIP), three major requirements 
must be met for diagnosis based on the American Thoracic Society/Europhean Respiratory 
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Society concensus: 1) Exclusion of other causes of pulmonary fibrosis such as environmental 
exposures, drug toxicity or connective tissue disease 2) Associated abnormalities on high 
resolution CT or chest radiography 3) Impairment on pulmonary function tests 3, 4. Patients 
typically present with a history of greater than 3 months of dyspnea and a non-productive cough. 
On physical exam, bilateral dry inspiratory crackles may be appreciated at the lung bases. Chest 
radiography shows ground glass opacities and CT analysis shows irregular thickening of the 
alveolar septa. As fibrosis of the lung progresses, the normal lung architecture becomes distorted 
under the tension of the fibrosis. This change is often described as a “honeycomb” appearance of 
the lung12. Histologically, IPF has a pattern of Usual Interstitial Pneumonia (UIP), which is 
characterized by areas of immature and mature fibrosis (temporal heterogeneity) and alveolar 
inflammation with intervening areas of normal tissue architecture12. On H&E staining, 
myofibroblastic foci are present, which are light-staining areas of spindle-shaped mesenchymal 
cell expansion among collagen and matrix deposition. These foci are randomly dispersed 
throughout the lung and are a marker of active disease12. Inflammation is also present and is 
assessed through bronchoalveolar lavage and interstitial microscopy which shows the presence 
of macrophages, neutrophils, eosinophils, mast cells and limited lymphocytes2, 12.  
1.1.3 Treatment 
 The primary cause of clinical deterioration and mortality in IPF patients is respiratory failure 
(38.7%), followed by heart failure (14.4%), bronchogenic carcinoma (10.4%), ischemic heart 
disease (9.5%), infection (6.5%), and pulmonary emboli (3.4%)2, 13. Despite recent studies and 
advances in the understanding of the pathogensis and clinical course, there are currently no 
effective therapies for IPF, aside from lung transplantation. Several options are available, such as 
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anti-inflammatories, however there are very few to no clinical studies that show significant 
improvements (some partial and transient) in progression-free survival, functional improvement 
or an increase in quality of life14. Over the last 50 years, corticosteriods have been commonly 
utilized to control inflammation. In retrospective studies, Flaherty et al. report that fewer than 
20% of patients had improvement with corticosteroid therapy and that the severe side-effects of 
steroids were encountered including weight gain, osteoporosis, and hyperglycemia15, 16. Chronic, 
low dose prednisone may be a maintenance therapy in responsive patients but is not 
recommended for all IPF cases3, 14.  
Immunosuppressive/cytotoxic agents, such as azathioprine and cyclophosphamide, are 
used in patients who are non-responsive to or cannot take corticosteroids. These agents have 
shown favorable results in 15-20% of IPF cases4. Azathioprine is a purine analog that inhibits 
adenine deaminase to impair leukocyte proliferation14. Raghu et al. completed a small 
comparative 1-year study of high dose prednisone therapy versus hight dose prednisone plus 
azathioprine in IPF patients. While there was slightly less mortality in the azathioprine group 
when adjusted for age, they found no significant differences in clinical measures, such as forced 
vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO), with any of the 
therapies17. Cyclophosphamide is a cytotoxic alkylating agent and has shown no survival benefit 
in studies18, 19. The side-effect profile and toxicity are profound14, 18 and limits the utility of 
cyclophosphamide. Due to the minimal efficacy of these immunosuppressive agents, the role of 
inflammation as a major driving force in IPF continues to be highly debated. Additional 
comination studies with these agents may be necessary. 
Finally, anti-fibrotic agents such as colchicine and interferon gamma, have been tried but 
unsuccessful in humans. Colchicine functions by decreasing collagen formation in fibroblasts 
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and suppressing growth factor release by alveolar macrophages14. While colchicine showed 
promise in vitro and in animal models of pulmonary fibrosis20, 21, it has shown no survival or 
lung function benefit in clinical IPF22, 23. In a combination therapy study, Fiorucci et al. report 
finding no clinical improvements with prednisone alone or prednisone with either colchicine or 
cyclophosphamide in patients with early stage IPF24. While many of these drugs are used as 
monotherapies or in combination, there have been no prospective placebo-controlled randomized 
trials performed.  
Amist the grim outlook of current therapies, the IPF research community continues to 
find new molecular targets. Pirfenidone, although not available in the United States or Europe, 
was successful in abrogating bleomycin-induced fibrosis in animal models25, 26 and shows 
potential for improving or stabilizing lung function in IPF patients27. Lung transplantation is the 
only current option that prolongs survival in IPF patients. Considerations for lung 
transplantations should be made early on in the disease course, as the wait list time is around 46 
months, during which time many patients with advanced disease die prior to transplant3, 14. The 5 
year survival post-transplant is approximately 40%28.   
1.1.4 Asbestosis – A related fibrotic lung disease. 
While the cause of 41-70% of cases of pulmonary fibrosis is unknown, some are due to 
environmental or occupational inhalation of asbestos29. Asbestosis is a prototypical 
pneumoconiosis that causes significant morbidity and mortality in patients and increases the risk 
of lung cancer and mesothelioma30. Between 1940 and 1970, an estimated 27 million industrial 
workers were exposed to asbestos31. The intensity and duration of asbestos exposure is directly 
related to asbestosis development32. The majority of asbestosis and related-disease cases are 
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occupational exposures to the fibers. Workers in the cement, milling, insulation, shipyard and 
mining industries are at the highest risk of developing disease33. During the 1980’s, the United 
States placed restrictions on the use of asbestos, which has drastically decreased exposure risk34. 
However, the risk of asbestosis remains in developing countries, such as India, that lack 
regulations. The development of severe disease has a latency of 20-40 years; therefore, it still 
remains a significant health concern in the United States as exposed individuals may still develop 
disease. Currently, there is no treatment available for asbestosis. 
Asbestos is extremely chemical and heat resistant and has high tensile strength; properties 
which account for its industrial use. Various types of asbestos fibers can cause asbestosis. Fibers 
are identified through two main groups: amphiboles (crocidolite, amosite, tremolite, 
anthophyllite, and actinolite – straight fibers) and serpentines (chrysotile - curly fibers)35. All of 
the fiber types are fibrous silicates with variable mineral components including iron, magnesium, 
sodium and calcium.  Chrysotile accounts for greater than 95% of the fiber type used in US 
industry in the past30, 35. Amphiboles such as crocidolite were also used the U.S. and are more 
potent in causing disease, most likely due to their straight, non-pliable structure and the inability 
of the lung to clear them30. 
Histologically, asbestosis emulates the fibrosis pattern of idiopathic pulmonary fibrosis 
(IPF) with the additional presence of asbestos bodies in tissue sections. The fibrosis is primarily 
heterogeneous and patchy with a subpleural distribution in the bases of the lungs36. After 
inhalation, asbestos fibers get embedded in the lung parenchyma and alveolar macrophages 
attempt to phagocytose them. If the fibers are too large for the macrophage to digest, the fibers 
become asbestos bodies37, where they are coated in an ferrous-proteinous-mucopolysaccharide 
material making them appear as beaded rod-like structures. Asbestos bodies commonly form 
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during human disease but do not in mice37. These structures are less fibrogenic and cytotoxic 
than uncoated asbestos fibers37, which suggests that this is a compensatory host defense 
response. Another hallmark of asbestosis includes the presence of parietal pleural plaques with 
pleural thickening which suggest asbestos exposure32. 
Asbestos can lead to increased oxidative stress directly and indirectly. Asbestos fibers 
contain transition metals on their surface which can redox cycle and participate in direct ROS 
generation38, 39. This has led to the “amphibole hypothesis” that states that amphiboles participate 
in redox cycling through their high iron content and that this contributes to asbestos-induced 
inflammation, injury and fibrosis40, 41. Studies also show increased superoxide production 
indirectly through oxidative bursts from recruited neutropils and macrophages exposed to 
asbestos42, 43. Asbestos also causes injury through altering epithelial barrier function44, inducing 
apoptotic cell death45, 46 and activating inflammatory43, 47, 48 and fibrogenic pathways49, 50. 
Reactive oxygen species produced by asbestos fibers have been shown to activate profibrotic 
TGF-β in the lung39, 50, which is important in fibrosis development. 
1.2 EXPERIMENTAL ANIMAL MODELS OF PULMONARY FIBROSIS 
Pulmonary fibrosis is modeled in vivo using several injury models that involve a stimuli with 
subsequent alveolar injury, inflammation and fibrosis development. The stimuli commonly used 
are Bleomycin (intratracheal, subcutaneous, or intraperitoneal administration), asbestos and 
silica, which are administered intratracheally or via an inhalation chamber. Each animal model 
has advantages and disadvantages that should be considered when choosing a model to use in 
experiments.  
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1.2.1 Bleomycin 
Bleomycin is an antineoplastic antibiotic used in the treatment of lymphomas, testicular 
carcinomas and squamous cell carcinomas of the cervix, head and neck51, 52. One detrimental 
side effect is lung fibrosis, which has provided utility in the animal model. It is thought that lung 
toxicity occurs due to the low levels of bleomycin hydrolase, an enzyme active in Bleomycin 
inactivation and metabolism51, 52. Bleomycin forms a complex with redox-active iron, molecular 
oxygen and DNA, resulting in DNA strand breaks51. Bleomycin also produces superoxide and 
hydroxyl radicals that can damage cell membranes, lipids, and proteins53. Studies support the 
involvement of oxidative species as antioxidants can prevent the injury, such as N-acetyl-
cysteine and desferoxomine administration54 and extracellular superoxide dismutase 
overexpression55, a lack of ROS decreases fibrosis development56, and a lack of superoxide 
dismutase exacerbates the injury57.  
Pathologically, Bleomycin causes an acute neutrophilic inflammatory response in the 
lung between 1-3 days. The alveolar spaces become hypercellular and the inflammation switches 
to a chronic lymphocyte-predominant response58. The loss of epithelial cells results in 
subsequent fibrosis that begins around day 7 with the accumulation of fibroblasts and matrix 
deposition55, 57-59 and peaks between day 14 and 21. The fibrosis may resolve after day 21 which 
should be considered in experimental design. Regardless, Bleomycin is the most commonly used 
model. 
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1.2.2 Asbestos 
The mouse model of asbestosis60 produces a progressive, peribronchial and alveolar septal 
fibrosis with similar pathology to that seen in humans61 (temporal heterogeneity) and therefore 
provides an ideal way to study the mechanisms of asbestosis, IPF, and particle injury. Fiber size 
can range from 1-5μm in diameter and up to 200μm in length62. The disease course begins with 
an initial acute inflammatory response. Activated macrophages, neutrophils and eosinophils are 
present in the alveolar spaces within 24 hours of exposure63. The activated alveolar macrophages 
attempt to clear the fibers and some fail to engulf medium and large asbestos fibers. The 
leukocytes respond to the asbestos insult by releasing cytokines and reactive oxygen species43, 64, 
which can shift the oxidant/antioxidant balance. The fibers can remain for long periods of time in 
the lung interstitium and cause hyperplasia of Type II pneumocytes, fibroblasts, and smooth 
muscle cells62, 65. By day 7, peri-bronchial fibrosis and alveolar septal thickening in a temporally 
heterogeneous pattern begins to form through deposition of collagen, elastin and matrix 
components66, 67. The fibrosis is progressive and is unresolved out to 1-year post-asbestos 
exposure (unpublished observation from the laboratory of Dr. Tim Oury). Several benefits of the 
asbestos model over the Bleomycin model include: 1) the presence of fibers in BALF and 
histological sections of lung which confirms that the animal was treated; 2) the fibrosis is 
progressive and does not resolve, unlike Bleomycin.  
1.2.3 Silicosis 
Silicosis is another type of pneumoconiosis in humans, which has been utilized as an animal 
model of lung injury.  Silica (SiO2) is a crystalline tetrahedral particulate that can enter the distal 
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respiratory tract and cause fibrosis in humans and animals68. Similar to the asbestos model, 
intratracheal instillation of silica results in an acute accumulation of inflammatory cells 
(neutrophils, macrophages, lymphocytes, and occasional eosinophils) in the alveolar spaces and 
interstitium69-71, damage to epithelial cells72, 73, and subsequent collagen deposition74-76 and 
fibrosis development76, 77. The fibrosis is characterized by silicotic nodules with a core of 
hyalinized collagen and fibroblasts68. Activated leukocytes play a large role in the production of 
cytokines and growth factors, such as TNF-α and TGF-β, that are believed to be involved with 
the injury and repair78-80. 
1.3 THE PATHOGENESIS OF PULMONARY FIBROSIS 
The underlying processes of pulmonary fibrosis are currently thought to involve the presence of 
a persistent stimuli or injury and dysregulated repair of the lung that results in fibrosis2. The role 
of inflammation remains unclear. In idiopathic pulmonary fibrosis, the lack of an identifiable 
cause creates a challenge for studying pathogenesis. The asbestos and bleomycin animal models 
discussed previously offer insight to the pathogenesis.  
1.3.1 Re-epithelialization and Alveolar Wound Healing 
Type I epithelial cells comprise 95% of the alveolar surface in the lung81, 82. They create the tight 
junctions of the lung and are critical for gas exchange. Type II cells are cuboidal pneumocytes 
that are progenitor cells for type I cells and function to produce proteins for the lung such as 
surfactant82. Epithelial injury is thought to be one of the initial steps in the pathogenesis of 
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pulmonary fibrosis. Furthermore, analysis of UIP lung biopsies revealed a significant loss in type 
I epithelial cells in fibroblastic foci and areas of lung deterioration, along with increases in 
epithelial apoptosis markers83. The loss of alveolar epithelial cells has several effects81. When 
Type I cells are lost, the gas exchange and permeability barrier becomes disrupted and allows 
fluid leak in and out of the lung. This also allows for the entry of migrating leukocytes and 
interstitial fibroblasts. The loss of type II cells results in a decreased progenitor cell population 
for replacing epithelial cells and a decrease in active transport abilities of the cell surface81. After 
epithelial cell death, the basement membrane of the alveolar surface is left denuded and exposed. 
Apoptosis is thought to occur in IPF alveolar epithelial cells through pro-apoptotic signaling of 
Bid and Fas-ligand84, 85.  
Epithelial wound healing or re-epithelialization is a concerted effort by various cells 
types to restore the lung after an injury or cell death. Mesenchymal cell, such as myofibroblasts, 
undertake matrix synthesis to form a suitable scaffold upon which epithelial cells can repopulate 
lost cells. Integrins are membrane bound receptor proteins that aid cells in cell-cell and cell-
matrix interactions and are critical in coordinating the healing process through the migration, 
proliferation and differentiation of cells81, 86. Integrins are heterodimeric proteins composed of α 
and β subunits. There are approximately 18 different α subunits and 8 β, that are expressed by a 
variety of cells types and have variable ligand affinities86. For example, αvβ6 is restricted to 
epithelial cells and α1β1 is more ubiquitously expressed with a high binding affinity for 
collagen86.  
The role of integrins in pulmonary fibrosis is suggested in both human IPF86-88 and 
animal models89-91. Abnormal integrin signaling has been seen in fibroblasts from IPF patients88. 
In the Bleomycin model, neutralizing antibodies against integrins are capable of reducing 
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fibrosis and lung injury91, 92. Integrins may also modulate the biological activity of growth 
factors. Sheppard et al. show that integrin αvβ6 is involved in the binding and activation of 
latent TGF-β during pulmonary fibrosis and that mice lacking this integrin have exaggerated 
inflammation but diminished fibrosis development90, 93. Additional research is required to 
explore the potential roles of integrins in pulmonary fibrosis. 
1.3.2 Inflammation 
The role of inflammatory cells in pulmonary fibrosis is a controversial issue. Therapeutic studies 
that target inflammation, such as corticosteroids, have failed to show clinical benefits15, 19, 23. 
However, several studies have highlighted associations between the presence of inflammatory 
cells and disease prognosis. Neutrophilia and eosinophilia are seen in the bronchoalveolar lavage 
fluid (BALF) of 70-90% and 40-60% of IPF patients, respectively3. This increase in 
inflammatory cells has been associated with a worse prognosis and mortality in some clinical 
studies7, 94, 95. Immune activation and inflammation have been shown to play an important role in 
fibrosis models48, 79.  
When the lung is challenged with a stimuli such as asbestos, additional leukocytes are 
recruited acutely to aid in re-establishing lung homeostasis. Inflammatory cells can damage the 
lung through the release of oxidative species, proteases (i.e. matrix metalloproteinases, elastase), 
peroxidases (i.e. myeloperoxidase), cytokines and growth factors96, 97. This suggests that 
inflammation can contribute to a pro-fibrotic environment, affecting the wound repair process 
and the extent of remodeling. An acute inflammatory phase is a characteristic part of asbestos 
and Bleomycin-induced models43, 57, 58, 63. Studies suggest that chemotactic factors and 
neutrophils, which are characteristic of this acute phase, are present in IPF98, 99. The role of 
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inflammation has not been delineated in human disease, which likely explains why pulmonary 
fibrosis is still considered to be a disease of abnormal wound repair. 
1.3.3 Growth Factors and Cytokines 
Growth factor and cytokines/chemokines produced by the epithelium have been implicated in 
pulmonary fibrosis. The alveolar epithelium produces mediators such as TGF-β100-103, platelet-
derived growth factor (PDGF)104, 105 and TNF-α96, 104, 106, that alter the microenvironment of the 
lung. Unregulated local production of these mediators can mediate fibrogenesis and 
inflammation in the lung. Transforming growth factor-β (TGF-β) is a profibrotic protein released 
primarily by alveolar epithelial cells and macrophages within the lung. TGF-β has multiple 
functions including inducing the expression of collagens, proteoglycans and matrix components 
by fibroblast/myofibroblasts59, 102, 107, is chemotactic to macrophages and fibroblasts, and can 
stimulate further cytokine production. Studies show that increased expression of this protein in 
alveolar epithelial cells leads to the development of fibrotic lesions102. TGF-β has also been 
shown to regulate inflammatory responses. It can drive Tcells toward a TH-helper 17 phenotype 
by increasing the cellular response to cytokines, such as IL-23, which promote the resolution of 
inflammation108. It also decreases superoxide production by macrophages109, which have a key 
role in inflammatory responses. Kahlil et al. suggest that TGF-β1 expression occurs in epithelial 
cells and macrophages in IPF lung and epithelial expression occurs only after chronic lung 
injury100. TGF-β signals through intracellular Smad intermediates. Profibrotic Smads (Smads 2, 
3, and 4) are increased in bleomycin-induced lung fibrosis, while anti-fibrotic Smad7 is 
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decreased110. Smad3 null mice are also resistant to TGF-β-induced pulmonary fibrosis111, 
supporting the role for TGF-β signaling in fibrosis development. 
Platelet derived growth factor (PDGF) is secreted by alveolar epithelial cells and induces 
the migration, growth and ECM synthesis of fibroblasts and smooth muscle cells105. PDGF is a 
polypeptide formed by two chains (PDGF-1, A and PDGF-2, B). Studies have reported 
significant increases in PDGF-2 mRNA expression in alveolar epithelium from IPF lungs105. 
Tumor necrosis factor (TNF-α) is a pro-inflammatory cytokine that has been implicated in 
pulmonary fibrosis112, 113. TNF-α transgene expression in alveolar epithelial cells leads to 
fibrosis development114. It has also been linked to NF-κB activation in asbestos-induced 
fibrosis115 and has a suggested role in eosinophil recruitment and activation106.  
1.3.4 Fibroblasts, Matrix Deposition and Turnover. 
The mesenchymal cell population is an active participant in remodeling of the lung in IPF. 
Fibroblast expansion and excessive productivity of matrix components are features of pulmonary 
fibrosis116, 117. Spindle-shaped myofibroblasts are characterized by the expression α-smooth 
muscle actin, increased collagen production and cytokine gene expression, and increased 
contractile properties118. Myofibroblasts appear during the active phases of fibrosis and the 
presence of these specialized cells has been documented both in human pulmonary fibrosis and 
animal models107, 116, 117, 119. Myofibroblasts are potentially derived from 3 origins, the last two 
options being controversial: 1) fibroblasts directly differentiating into myofibroblasts by gaining 
additional characteristics of smoth muscle cells 2) epithelial-mesenchymal transition (epithelial 
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cell transdifferentiation to myofibroblasts)89, 120, 121 3) from circulating fibrocytes or bone marrow 
progenitor cells122.  
The extracellular matrix (ECM) is critical for maintaining a strong structure that can 
withstand mechanical stretch and recoil of the lung. Matrix deposition occurs primarily through 
fibroblasts and myofibroblasts but can involve endothelial and epithelial cells. The ECM is 
composed of various molecules including collagen, elastin, fibronectin, proteoglycans (discussed 
in section 1.7), hyaluronan, and laminin81. Pulmonary fibrosis is characterized by often drastic 
changes in the extracellular matrix, which can be the result of excessive deposition (an increase 
in collagen deposition2, 116, 117), an impairment in ECM degradation and resolution or a 
combination of these two. Thus, ECM changes become very complex over the pathogenic course 
of IPF. 
1.3.5 Matrix Metalloproteinases 
ECM degradation and turnover is regulated by the activity of matrix metalloproteinase 
enzymes (MMPs) and their tissue inhibitor counterparts (TIMPS). MMPs are matrix degrading 
proteinases (currently a total of 22) that have been shown to be upregulated in models of 
pulmonary fibrosis123, 124. The substrates of MMPs are extracellular matrix components and 
soluble factors and include, but are not limited to, the following: 1) MMP 1, 8 and 13 are 
collagenases targeting collagens I, II, III, VII, X, gelatin and pro-TNF-α; 2) MMP 2 and 9 are 
gelatinases targeting type IV and V collagen, gelatin, elastin, fibronectin, pro-TGF-β, and pro-
TNF-α; 3) MMP3, 10 and 11 are stomelysins that target proteoglycans, laminin, fibronectin, 
gelatin and pro-TNF-α; and 4) MMP 7 (matrilysin) targets proteoglycans, collagens, laminin, 
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decorin, gelatin, and fibronectin125. The majority of MMPs are synthesized as proenzymes and 
activated by proteolysis of a cysteine-zinc pro-domain, called a “cysteine switch”125, 126. Reactive 
oxygen species are also capable of activating MMPs, increasing their transcription, and 
deactivating proteases126-128. Thus, oxidants may play a significant role in unregulated activity of 
MMPs in pulmonary fibrosis. Tissue inhibitors of metalloproteinases (TIMPs 1-4) are 
extracellular or membrane bound enzymes that bind tightly to MMPs to inhibit their degradative 
activity125. 
In IPF patients, MMP 2 and 9 and TIMPs 1 and 2 are elevated in areas of alveolar 
damage and at disrupted basement membranes129. McKeown et al. report increases in MMP 3, 7, 
8 and 9 in BALF from IPF patients with levels higher in patients with earlier mortality130.  Rosas 
et al. report increases in MMP1 and 7 in serum, BALF and lung tissue in IPF patients, suggesting 
they may be blood biomarkers for IPF131. Increases in MMP7 expression have also been 
reported132. Animal studies show similar results with increases in MMP2 and 9 in the fibrotic 
phase of bleomycin-induced fibrosis123. Cabrera et al. report that an over-expression of MMP9 
diminishes bleomycin-induced fibrosis133. While there are differences in findings related to the 
role of MMPs in pathogenesis, the balance of MMPs and TIMPs is likely complex along the 
course of fibrogenesis in the lung.  
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1.4 CARDIAC FIBROSIS AND CARDIOMYOPATHY 
1.4.1 Causes and Pathophysiology 
The most common cause of myocardial dysfunction is a primary or secondary dilated 
cardiomyopathy (DCM)134. The WHO characterizes dilated cardiomyopathy as the dilation and 
impaired contraction of the left ventricle or both and causes of DCM include idiopathic, viral 
and/or immune, alcoholic/toxic, or associated with another cardiovascular disease135. DCM 
typically presents with progressive heart failure. One agent that leads to chronic remodeling and 
DCM is doxorubicin, an anthracycline chemotherapeutic agent used to treat a wide variety of 
cancers136, 137. The most common and dose-limiting side effect is the cardio-toxicity involving 
cardiac fibrosis that leads to non-ischemic dilated cardiomyopathy and congestive heart 
failure136. Doxorubicin-induced cardiac injury and fibrotic remodeling in the heart are thought to 
involve reactive oxygen species (ROS) and oxidant/antioxidant imbalances. The cytotoxic 
activity of doxorubicin comes from its intercalation within DNA, which causes single and double 
strand breaks.  
The primary mechanism of doxorubicin-induced myocardial damage involves the 
generation of oxidative stress through quinone-semiquinone reduction-oxidation reactions138. 
Single election reduction of a ring within the structure of doxorubicin results in a semiquinone 
radical that further reduces oxygen forming superoxide radicals139. Intracellular radical 
generation has been shown with doxorubicin, however, the role of extracellular radicals remains 
unclear. Cellular ultra-structural pathology includes cytoplasmic vacuolization and loss of 
myofibrils140.  
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1.4.2 Diagnosis, Pathological Findings and Treatment Options 
Doxorubicin-induced cardiac fibrosis and dilated cardiomyopathy can occur at any point during 
the doxorubicin treatment process, from soon after initial treatment to months or years after the 
discontinuation of the drug. A total dosage of doxorubicin as low as 250mg/m2 can cause toxicity 
and more than 30% of doxorubicin-recipients develop cardiac dilation and ventricular failure139, 
140. There are currently no therapies for the prevention or treatment of this cardio-toxicity. 
Patients are followed through baseline and follow-up cardiac functional testing via 
echocardiography140. If decreases in ejection fraction and associated symptoms develop, 
treatment must be discontinued, however this does not preclude further progression of fibrosis. 
Patients who develop severe heart failure require heart transplantation136. Studies suggest that 
adding antioxidants, such as flavonoids or Vitamin C and E, to dox administration may help to 
prevent the cardiac injury141, 142. Despite this detrimental side-effect of doxorubicin treatment, it 
is still used in combination chemotherapy regimens because of its anti-tumor efficacy143. 
Additional studies are required to understand the roles of key antioxidants so that better 
strategies can be developed to limit dox cardiac toxicity.  
1.4.3 Doxorubicin Experimental Animal Model of Cardiac Fibrosis. 
Doxorubicin cardiac injury progresses to fibrosis of the left ventricle. Typical dosing in animals 
ranges from 15-25 mg/kg per animal via intraperitoneal injection. The literature describes an 
important role for free radicals in the development of cardiac damage induced by doxorubicin143. 
Doxorubicin also decreases glutathione peroxidase antioxidant activity and protein levels in 
animal models144. Apoptosis has been proposed as a mechanism of doxorubicin-induced cell loss 
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and dysfunction and is oxidatant dependent (H2O2-mediated)138, 145, 146 and independent147. The 
doxorubicin model provides a model of oxidant mediated cardiac fibrosis to study pathogenesis. 
1.5 OXIDATIVE STRESS AND REACTIVE OXYGEN SPECIES 
Oxidative stress is defined as the imbalance of oxidant species and antioxidant mechanisms, 
where oxidants dominate and can lead to tissue damage and cellular dysfunction. Free radicals 
are species that contain one or more unpaired electron allowing them to react with other 
molecules. Reactive oxygen species (ROS) are reduction-oxidation reaction and free radical 
products of oxygen and can be produced through electron leak from mitochondrial metabolism, 
enzymatic reactions (xanthine oxidase) and released from activated leukocytes134, 148. ROS have 
the ability to react with local lipids, proteins, DNA, etc, to alter their structure and function. 
Reactive nitrogen species (RNS) are products of nitrogen reactions and are briefly discussed.  
When considering oxidative stress, the lung is unique due to its exposure to higher 
oxygen tensions than other tissues. The oxygen pressure of inhaled air is 20kPa (150 mm Hg). 
Pressures in venous blood flow are around 6kPa (45 mm Hg) and may be as low as 0.13kPa in 
some tissues, while the oxygen at the alveoli of the lung is ~13.3 kPa (100 mm Hg)149. Thus, the 
lung is constantly facing high oxygen tensions and oxidative insults. Unregulated production of 
ROS and RNS in the lung and other tissues can lead to an imbalance in oxidants to antioxidant 
species resulting in oxidative stress and nitrosative stress respectively.  
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1.5.1 Reactive Oxygen Species 
Diatomic oxygen O2 is considered to be a free radical species because it has 2 unpaired electrons 
(di-radical). While not very reactive itself, oxygen can undergo a sequence of one-electron 
reductions to achieve more reactive oxygen by-products: 
 
Free radical superoxide (.O2-) is formed from one-electron reduction of oxygen and can 
undergo a subsequent one-electron reduction, as depicted above, or dismutation either 
spontaneously or through enzyme catalysis (superoxide dismutases) to form hydrogen peroxide 
(H2O2)134, 148. Superoxide is not as damaging as other radical species but is important in their 
production such as H2O2 and hydroxyl radicals. While H2O2 is not a free radical, it is still a 
common reactive oxygen species albeit less reactive than hydroxyl radicals. A unique feature of 
H2O2 is that it can traverse cell membranes freely.  Therefore, gaining it access to signal within 
the cell and damage intracellular organelles, proteins, and DNA. Additional single electron 
reductions of H2O2 form hydroxyl radical (.OH), which is the most reactive species, and finally 
H2O. Hydroxyl radical can be formed from the reaction of H2O2 with metal ions or breakdown of 
peroxynitrite (see section 1.5.2). It is one of the most reactive radicals and acts on local 
substrates at reaction rate between 107–1011 M-1s-1  134. The half-life of hydroxyl radical is in the 
milliseconds range. The Fenton and Haber-Weiss reactions are the two most important 
mechanisms for the generation of hydroxyl radicals from transition metals. The Haber-Weiss 
reaction generates hydroxyl radicals from hydrogen peroxide and superoxide134, 148.  
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 The Fenton reaction involves transition metal catalysis. Metals such as iron are typically 
bound to proteins and not readily free within the body to participate in these types of reactions. 
Therefore, this step may not occur as frequently. Asbestos fibers offer a unique reduction-
oxidation potential because they contain varying amounts of free iron that can catalyze ROS 
production. Crocidolite and amosite asbestos fibers can contain up to 27% iron, where as 
chrysotile is between 1-6%150. Indeed, free radical production has been observed with asbestos in 
cell and cell-free systems38, 42.  
Within the laboratory, hydroxyl radicals can be generated through a Fenton-like system 
utilizing copper(II) sulfate and hydrogen peroxide151. Step 1, in figure 1 below, involves 
production of superoxide from oxidation of H2O2 and reduction of copper(II) to copper(I). In step 
2, superoxide can further reduce additional Cu(II) to replenish Cu(I) within the system. In step 3, 
the reduction of hydrogen peroxide forms hydroxyl radicals via a Fenton-like reaction. Free 
radical production can be controlled by the presence of extracellular superoxide dismutase (EC-
SOD), which scavenges superoxide. In the asbestos model of pulmonary fibrosis, free radicals 
are produced within the lung. We utilize the copper(II) sulfate and hydrogen peroxide system to 
model this free radical generation in vitro. 
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 Figure 1: Generation of Hydroxyl Radicals Through a Fenton-like Copper Sulfate System: CuSO4 
and H2O2 are utilized to generate superoxide and hydroxyl radicals in vitro. Step 1: the production of superoxide 
from oxidation of H2O2 and reduction of copper(II) to copper(I); step 2, superoxide can further reduce additional 
Cu(II) to replenish Cu(I); step 3, the reduction of hydrogen peroxide forms hydroxyl radicals via a Fenton-like 
reaction. 
In vivo, other mechanisms for free radicals and ROS generation include electron leak 
from mitochondrial metabolism, enzymatic reactions (xanthine oxidase) and released from 
activated leukocytes through oxidative bursts148. The mitochondrial respiration chain culminates 
with the transfer of electrons to oxygen. Electrons can leak from this system and reduce oxygen 
to generate superoxide, which can undergo further reduction to form additional ROS. 
Intracellular scavenging enzymes help to balance this oxidative stress on the cell. Enzymatic 
production of ROS is highlighted through xanthine oxidase reaction with hypoxanthine in the 
presence of O2, producing superoxide, xanthine, urate and H2O2. The importance of xanthine 
oxidase has been shown in both cardiovascular ischemia/reperfusion152-154 and pulmonary 
injury155-157. 
Another primary source of large amounts of ROS are activated leukocytes (neutrophils, 
macrophages, eosinophils). The innate function of the leukocyte is to remove microorganisms 
through phagocytosis to protect the body from infection. Once a foreign body is ingested, the 
leukocyte produces an “oxidative burst” of ROS through an NADPH oxidase complex at the cell 
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membrane. The oxidase catalyzes one or two electron reductions to form superoxide and H2O2, 
respectively, see below, that can kill a microbe or damage host tissues if released from the cell148, 
158, 159. Not only can the ROS damage tissues but they are involved in intracellular and 
extracellular signaling that can alter cell functions158, 160. 
 
Myeloperoxidase (MPO) is a second enzyme found in neutrophil azurophillic granules 
that aids in bacterial killing and can participate in redox reactions. MPO utilizes H2O2 and 
chloride ions to produce toxic hypochlorous acid (HOCl) or bleach.  
 
MPO has been implicated in cardiovascular damage, oxidative modifications to proteins 
in vessel walls and in atherosclerosis161, 162. MPO is a highly cationic enzyme allowing it to 
localize to cell surfaces, especially endothelial surfaces, through interactions with 
glycosaminoglycan chains. HOCl can participate with hydroxyl radical in the fragmentation of 
extracellular matrix components such as hyaluronan and glycosaminoglycan side chains like 
heparan sulfate163-165. MPO has also been shown to catalyze the metabolism of nitric oxide (.NO) 
to nitrite (NO2-) through radical intermediates166. Eosinophil peroxidase is the eosinophil 
equivalent of MPO and has similar biological activity. 
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1.5.2 Reactive Nitrogen Species 
The excess of reactive nitrogen species within a system leads to nitrosative stress. Nitric oxide 
(.NO) is an important nitrogen species produced by nitric oxide synthase enzymes through 
metabolism of L-arginine. There are three NOS enzymes, two of which are constitutively 
expressed: endothelial eNOS, neuronal nNOS (both constitutive) and inducible iNOS. Twenty 
times more .NO is produced by iNOS than the other enzymes148. iNOS activity is induced by 
external stimuli such as bacterial lipopolysaccharide167. Nitric oxide and iNOS are important in 
both pulmonary fibrosis168, 169 and doxorubicin-induced cardiac toxicity170, 171.  
The radicals produced by reduction of oxygen can react with freely diffusible nitric oxide 
to form additional radical species (see the following diagram), in effect inactivating nitric oxide, 
which is a potent signaling molecule (i.e. the inactivation of NF-κB172) and vaso-relaxant167. 
Peroxynitrite anion (ONOO-) can be formed through the reaction of superoxide with nitric oxide 
(.NO) or by reactions between hydrogen peroxide and nitrite. Peroxynitrite is a powerful oxidant 
that can modify tyrosine residues producing nitro-tyrosine and oxidize thiols. At a physiologic 
pH, the protonated form of peroxynitrite (peroxynitrous acid) will decompose into hydroxyl 
radical and nitrogen dioxide. One electron reduction reactions of .NO will form nitrite, nitrogen 
dioxide, and nitrate.  
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 1.5.3 Antioxidant Defenses 
The lung and heart are continuously exposed to oxidative stress. A high oxygen tension in the 
lungs makes it particularly vulnerable to altered oxidant levels. The body uses several 
mechanisms to protect cells by counter-balancing oxidants134. There are three superoxide 
dismutase (SOD) enzyme isoforms including intracellular CuZn SOD (SOD1), mitochondrial 
manganese MnSOD (SOD2), and extracellular CuZn SOD (SOD3) that catalyze the dismutation 
reaction of superoxide to produce H2O2. CuZnSOD or SOD1 is found in the cytosol, nucleus, 
peroxisomes and mitochondrial inner membrane and functions to reduce intracellular levels of 
ROS173, 174. MnSOD is found within mitochondria to eliminate ROS produced by mitochondrial 
respiration173. Extracellular SOD is covered in more detail in section 1.6. Catalase, another 
antioxidant enzyme, catalyzes the reduction of H2O2 to H2O. Glutathione peroxidase catalyzes 
the oxidation of thiol-containing glutathione to GSSG by H2O2. It is also capable of 
decomposing other organic peroxides175. Additional molecules such as vitamins (i.e. Vitamin A, 
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ascorbate or Vitamin C, α-tocopherol or Vitatmin E) and albumin can also regulate levels of 
reactive species directly or indirectly by interacting with intermediates, such as albumin binding 
MPO175. Metal binding proteins or chelating agents (i.e. transferrin, lactoferrin, desferoxamine) 
can also effectively remove metals that would otherwise participate in reduction-oxidation 
reactions 134, 148, 175 and the production of oxidative and nitrosative species. 
1.5.4 Oxidative Stress in Fibrosis 
Oxidative stress has been implicated in many diseases such as pulmonary fibrosis6, 9, 11, 176, 
cardiac injury139, 142, 177, neurodegeneration178, 179, and aging180-182. Several studies have found 
evidence of increased oxidative stress in idiopathic pulmonary fibrosis. Increased markers of 
oxidative stress in have been reported in bronchoalveolar lavage fluid (BALF) of IPF patients (8-
isoprostane)183, as well as, in exhaled breath condensate (hydrogen peroxide and 8-
isoprostane)176 and were negatively correlated with pulmonary function in both studies. 
Decreased antioxidant enzyme status in patients with IPF has also been reported, such as 
decreased glutathione levels in alveolar epithelial lining fluid6, 184. Kunnula et al report 
significant decreases in extracellular SOD in fibrotic regions of UIP lungs61, which suggests that 
oxidative stress would be increased in these areas.  
Animal models of pulmonary fibrosis have offered opportunities to further evaluate the 
role of oxidative stress. In both models of Bleomycin- and asbestos-induced pulmonary fibrosis, 
extracellular superoxide dismutase protects against inflammation and fibrosis development57, 63, 
185. The extracellular matrix, such as hyaluronan, of the lung is also sensitive to oxidative stress 
during pulmonary fibrosis186. 
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Oxidative stress is central to the pathogenesis of cardiac fibrosis caused by ischemia 
reperfusion injury such as myocardial infarction and by doxorubicin-induced cardio-toxicity. 
Doxorubicin treatment in patients causes increases in free radical species138, 187, 188 and has been 
shown to decrease the expression of cardiac antioxidants139, 144. Supplementation with vitamin E, 
C, and A have provided antioxidant protection against cardiomyocyte death and have improved 
survival in CHF models and doxorubicin-induced injury142, 189. In vitro cardiomyocyte studies 
suggest that superoxide dismutase-like and glutathione peroxidase-like compounds can protect 
against free radical production and cellular apoptosis due to doxorubicin145, 190. 
Research has identified several potential mechanisms through which the presence of 
oxidative stress in the heart and lungs can lead to increased inflammation and fibrosis. Reactive 
oxygen species can alter inflammation through the activation of nuclear factor-kappa B (NF-κB) 
and activator protein-1 (AP-1)41, 191. These redox sensitive transcription factors can bind to 
promoter regions in DNA and control the gene expression of a host of genes including those 
controlling pro-inflammatory cytokines, growth factors and apoptotic signals191. NF-κB 
activation occurs in alveolar epithelial cells after asbestos exposure47, 115. Oxidative stress is also 
evident in the fibro-proliferative response. In vitro, H2O2 can stimulate the proliferation of 
cultured human fibroblasts192. Furthermore, fibroblasts isolated IPF lung are capable of inducing 
apoptosis in epithelial cells in vitro119, further promoting the cycle of alveolar damage and 
abnormal repair. Hydrogen peroxide, as a diffusible factor, can lead to increased epithelial cell 
death, as well97. Finally, oxidative species can control the proteolytic degradation of ECM 
through the activity of matrix metalloproteinases and tissue inhibitors of MMPs123, 125.  
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1.6 EXTRACELLULAR SUPEROXIDE DISMUTASE 
Superoxide dismutases are antioxidant enzymes found throughout tissues of the body and 
function to scavenge superoxide radicals that can damage cellular and matrix components. 
Superoxide dismutase (SOD) was first described by and its reactions were further described by 
Fridovich and McCord in 1969193, 194. There are three SOD enzyme isoforms including 
intracellular CuZn SOD (SOD1), mitochondrial manganese MnSOD (SOD2), and extracellular 
CuZn SOD (SOD3). Extracellular superoxide dismutase (EC-SOD) was identified by Marklund 
et. al. in 1982 in human plasma, lymph, ascites, and cerebrospinal fluid195, 196.   
1.6.1 EC-SOD Structure and Function 
EC-SOD is an active scavenger of superoxide free radicals by catalyzing the dismutation of 
superoxide into hydrogen peroxide and oxygen. This occurs at a rate constant of >109 M-1s-1 197. 
EC-SOD also functions to preserve nitric oxide (NO) bioavailability within the cardiovascular 
system198 by removing superoxide that can deplete NO. EC-SOD is a homo-tetramer enzyme 
formed by disulfide bridges between two dimers199-201. Each monomer contains an enzymatic 
domain containing one Cu(II) and one Zn(II) ions202, a matrix binding domain, a N-linked 
glycation site and multiple free cysteines that determine the proteins structure and activity 
(Figure 2A). In human EC-SOD, monomers can be in an active or inactive form depending on 
their protein folding and Cys-mediated disulfide bonds201. Approximately 1% of EC-SOD in 
human aorta can be distinguished as an octamer and is very stable203. It is highly expressed in the 
lung and localizes to cell surfaces by binding to heparan sulfate species197, 204-207 and type I 
collagen151, 199 through its matrix binding domain (MBD). The MBD contains a sequence of 
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positively charged Arginine and Lysine residues near amino acid 210 that makes this site suitable 
for binding to highly negatively charged heparan sulfate side chains. Through this domain, 
tetrameric EC-SOD has variable affinity for the ECM. 
An important covalent disulfide bond is found at Cys219 within the C-terminus of EC-
SOD that allows dimerization of two subunits through the MBD200. Enzymatic cleavage of any 
of the four MBDs will decrease or abolish the affinity of EC-SOD for the matrix and cell 
surfaces (Figure 2B). EC-SOD has 3 heparin affinity types: no affinity (type A), low affinity 
(type B) and high affinity (type C). Trypsin or endoproteinase treatment of EC-SOD, which 
targets lysine residues, can abolish or weaken the matrix binding affinity of EC-SOD204. This 
supports the important role of the cluster of basic amino acids in the C-terminus of EC-SOD. 
On western blot analysis, EC-SOD from lung tissue homogenates runs as 2 distinct bands 
of full length and proteolyzed EC-SOD at 35 and 32 kDa respectively, under reduced 
conditions199. Under non-denaturing, non-reducing conditions, native EC-SOD migrates as a 
tetramer at approximately 125 kDa, while the disulfide-linked dimer migrates at 51kDa on a non-
reduced gel199, 200.  
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 Figure 2: Schematic of EC-SOD Structure and Heparin Affinity. A) The EC-SOD monomer contains 
an enzymatic functional domain (grey), a unique matrix binding domain at the carboxyl terminus (black) which is 
composed of arginine (R) and lysine (K) residues, variable free Cysteine residues that can participate in disulfide 
bonding (Cys), and an N-linked glycosylation site. B) EC-SOD tetramer affinity for the matrix. 
An EC-SOD gene variant has been implicated in increased risk for cardiovascular and 
ischemic heart disease. Studies report that an amino acid modification, EC-SODR213G arginine-
213 to glycine substitution, in the MBD of EC-SOD results in decreased binding affinity of EC-
SOD for the tissue matrix208-210. Individuals with this mutation have increased levels of 
proteolyzed EC-SOD in their serum209, 211.  Population studies suggest that 2-6% of individuals 
may carry this altered sequence, thus it is considered to be a common gene variant211, 212. A study 
from Denmark reports a 2.3 fold increase in the risk of ischemic heart disease in heterozygous 
individuals for EC-SODR213G  213.  
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The human EC-SOD gene has several regulatory regions including an antioxidant 
response element, a xenobiotic response element, an NF-κB regulatory element, and a 
glucocorticoid response element174, 198. The importance of these regions in expression regulation 
for EC-SOD is still unclear. Several stimuli are known to induce EC-SOD expression. In type II 
alveolar epithelial cells, TNF-α and IFN-γ are potent inducers of EC-SOD through NF-κB 
activation214. Vasoactive factors, such as nitric oxide from endothelial cells, endothelin-1, 
heparin, histamine and vasopressin can induce EC-SOD in smooth muscle cells215. TGF-β can 
down-regulate EC-SOD expression in dermal fibroblasts and abolish stimulatory effects of 
cytokines such as IFN-γ on EC-SOD expression216. TGF-β also decreases superoxide production 
by macrophages109, thus altering oxidative stress. PDGF and fibroblast growth factor (FGF) can 
similarly down-regulate EC-SOD expression in vascular smooth muscle cells215. Combinations 
of cytokines and growth factors may have variable effects on EC-SOD expression throughout 
acute and chronic phases of inflammation and fibrogenesis. 
1.6.2 Tissue Distribution and Turn-over of EC-SOD 
EC-SOD is found in most tissues and fluids with particularly high amounts in the lungs, heart, 
arteries, kidneys and placenta217-219. In tissues, EC-SOD is primarily secreted and maintained in 
the high affinity form with all MBDs intact219. In plasma, variable EC-SOD species can be found 
including no matrix affinity, low affinity and high affinity EC-SOD220, 221. Proteolytic 
modifications to the MBD219 and glycation of lysine residues222 can lead to the lower affinity 
species. The tissue half-lives of the three EC-SOD species have been reported as 85 hours for 
high affinity EC-SOD, 20 hrs for low affinity and 7 hrs for no affinity EC-SOD221.  
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EC-SOD can be localized to the vasculature especially arteries215, 223, 224, epithelium223, 
224, and on macrophages and neutrophils225. The human aorta is very abundant with EC-SOD, 
which makes up 70% of the SOD in this tissue224. Much of the vascular EC-SOD is produced by 
smooth muscle cells215. Within the lung, EC-SOD localizes to the endothelial matrix of 
pulmonary vessels, the epithelium of the airway and alveoli, and the matrix of the alveolar septa 
199, 223. 
1.6.3 EC-SOD in Pulmonary and Cardiovascular Disease 
EC-SOD has been implicated in the pathogenesis of pulmonary diseases involving 
oxidative stress185, 197, 199. EC-SOD plays a role in several models of pulmonary fibrosis 
including Bleomycin-induced and asbestos-induced fibrosis, both of which produce reactive 
oxygen species in the tissue. Our lab has noted the protective effect of native EC-SOD in the 
lung by utilizing EC-SOD knockout mice. Knockout mice lacking EC-SOD throughout their 
tissues have significantly more lung fibrosis, acute lung injury, and inflammation dominated by a 
neutrophil influx due to Bleomycin and asbestos intratracheal administration57, 60, 63. EC-SOD 
distribution in the lungs of wild-type mice also changes, as it is lost from the parenchyma where 
it normally resides and increases in air spaces in fibrosis models226, as well as, after hyperoxia4, 
and pulmonary bacterial infection226. Additional studies support a role for EC-SOD in the 
regulation of inflammation. EC-SOD null mice get significantly more neutrophilic inflammation 
in the lung following hemorrhage-induced lung injury227 and intratracheal lipopolysaccharide 
(LPS)228. In a bacterial pneumonia model of lung injury, EC-SOD may be brought in by 
activated inflammatory cells226.  
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EC-SOD has been shown to protect the heart from ischemic damage, hypertrophy, and 
inflammation177, 229-231. As an antioxidant, EC-SOD is important throughout the cardiovascular 
system. Studies show that a percentage of the population has a mutation in the matrix-binding 
domain that diminishes its affinity for the extracellular matrix232-234. These individuals have a 
higher risk for the development of cardiovascular and ischemic heart disease232. This suggests 
that these individuals would also be more susceptible to other oxidant-mediated injuries due to 
the loss of matrix-associated EC-SOD. In the heart, studies have found that EC-SOD is important 
in the prevention oxidative injury that may contribute to cardiac remodeling in the heart in 
myocardial infarction models and that it alters ex vivo heart function229, 230, 232, 235. EC-SOD also 
protects against LDL oxidation and the enzyme’s activity is reduced in patients with coronary 
artery disease236. EC-SOD gene transfer in a hind limb ischemia model suggests that EC-SOD 
improves tissue function and has a signaling role in tissue repair after ischemic injury237. The 
specific mechanisms by which EC-SOD protects against fibrosis and tissue damage in various 
organs, including the lung and heart, has been investigated however remain unclear.  
1.7 HEPARAN SULFATE PROTEOGLYCANS 
The extracellular matrix (ECM) is composed of 3 major components: collagens, adhesive 
glycoproteins, and proteoglycans82. Heparan sulfate proteoglycans are comprised of a 
membrane-bound core protein with attached sulfated polysaccharide side-chains238. Polyanionic 
proteoglycans, like heparan sulfates, have the ability to bind highly cationic proteins and 
transition metals. The binding of transition metals makes them potential sites for Haber-Weiss 
and Fenton-like chemistry within the body. Furthermore, cationic proteins such as 
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myeloperoxidase and eosinophil peroxidase bind to the ECM and are sites of additional radical 
production such as hypochlorous acid from Cl- and hydrogen peroxide164, 165.  
1.7.1 Family Members – syndecans and glypicans 
Heparan sulfate proteoglycans are separated into 2 major families: the syndecans and the 
glypicans. Syndecans (Syn 1-4) are composed of a core protein ~30-45kDa with an extracellular 
domain, transmembrane domain and cytoplasmic tail (Figure 3). Glypican is composed of a core 
protein ~60 kDa with a glycosyl phosphatidyl inositol (GPI) linkage and an extracellular domain 
that forms a globular protein structure due to disulfide bonding between 14 conserved Cys 
residues239. Both of these groups bear variable HS side chains that link to Ser-Gly regions within 
the core protein, adding to their complexity and diversity. The HS side chains can range from 5-
70kDa. These side chains are synthesized in a process that creates a linker region to attach the 
polysaccharide chain to the core protein, followed by enzymatic modifications that result in 
acetylation and sulfation239. The polysaccharide chain is comprised of alternating N-glucosamine 
(GlcNAc) and glucuronic acid (GlcA) residues; thus, are called glycosaminoglycans (GAGs). 
Heparin is a heparan sulfate-like glycosaminoglycan made by mast cells and is known for its 
anticoagulant activity. Structurally it contains N-glucosamine and iduronic acid as its most 
common disaccharides and is not typically bound to a core protein. HS is made by almost all 
cells and has anticoagulant activity however less than heparin238. Heparin is modified with more 
sulfate groups than HS is, which provides some resistance against degradation. The molecular 
weight of HS proteoglycans is increased by the presence of the core protein, however, the GAG 
or HS side chains can be fragmented into much lower molecular weight species. Heparin is 
smaller in size and is characterized as high or low molecular weight. HS side chains appear to be 
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important in leukocyte-endothelial interactions and the transmigration of leukocytes240, 241. 
Syndecans will be the focus of the remainder of this section. 
 
Figure 3: Syndecan Structure: Syndecans are composed of a transmembrane protein with a cytoplasmic, 
transmembrane and extracellular domain. Heparan sulfate side chains are linked to the core protein and contain 
variable amounts of sulfated residues. The extracellular portion of the core protein can be shed from the cell 
membrane by proteolytic cleavage. 
Syndecans can function in various ways within the ECM: 1) bind and localize soluble and 
insoluble ligands, i.e. growth factors, TGF-β, FGF, cytokines, EC-SOD; 2) act as a soluble 
paracrine or autocrine factor when the ectodomain is shed; 3) maintain receptor abilities for 
internalization of ligands; 4) facilitate leukocyte migration and trafficking239. Syndecans are also 
linked to the actin cytoskeleton and have key roles in controlling cellular migration, proliferation 
and homeostasis. Known ligands for syndecans that are of importance with regard to 
inflammation and fibrosis include TGF-β1 and 2, HGF, VEGF, PDGF-AA, FGF, cytokines and 
chemokines such as IL-8, MCP-1, TNF-α239, 242-244. Syndecans can also bind other ECM 
components such as fibronectin and laminin and can bind enzymes such as neutrophil elastase, 
tissue plasminogen activator and extracellular superoxide dismutase. Syndecan-1 and -4 can bind 
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elastase in dermal wound fluids protecting them from their inhibitors and modulating the 
proteolytic potential of the micro-environment245. 
Table 1: Syndecan Expression by Cell Type 
 
The syndecan family is comprised of 4 members that vary by their cellular expression 
patterns and functions (Table 1). Syndecan-2, on activated macrophages, binds macrophage-
produced growth factors, such as PDGF and FGF, and promotes their activity/signaling243. 
Syndecan-3 is found predominantly within the central nervous system. Syndecan-4 is 
ubiquitously expressed and has characterized signaling abilities through binding to PIP-2 and 
activation of PKC-α. In skin fibroblasts from scleroderma patients, enhanced ERK activation 
was dependent on syndecan-4 and resulted in induction of profibrotic proteins and ECM 
contraction246. Syndecan-4 expression has also been described in macrophages247. 
Syndecan-1 is expressed in epithelial cells. While the signaling potential of syndecan-1 is 
unclear, HGF binding to syndecan-1  appears to promote activation of PI3-kinase and MAP-
Kinase pathways248. Syndecan-1 has an evident role in inflammation and wound healing249. 
Syndecan-1 expression can be upregulated in activated peritoneal macrophages and mediate their 
adhesion to cell surfaces250. Mice with global knock out of syndecan-1 are viable and have 
impaired wound healing and abnormal leukocyte-endothelial cell adhesion properties241, 245. 
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Syndecan-1 null animals also display inhibition of keratinocyte proliferation and migration in 
dermal wound models251, 252. Over expression of syndecan-1 led to a deficit in keratinocyte 
proliferation only251. These studies suggest that syndecan-1 has an important role in organizing 
and remodeling newly laid cells and that there is an optimal expression level required for the 
regulation of cell proliferation. TGF-β can induce the expression of syndecan-1 in epithelial 
cells253. In cardiac remodeling, syndecan-1 expression changes in models of myocardial 
infarction254 and increased syndecan-1 expression protects the heart from dilation and 
remodeling255. Thus, syndecan-1 appears to be important during the repair process in the heart 
and potentially the lung epithelium. 
1.7.2 Syndecan Biochemistry 
Receptors that may be involved in syndecan interactions include Toll-like receptor 4 and 
integrins. TLR4 is a receptor that initiates innate and adaptive immune responses to microbes. Its 
signaling modulates neutrophil migration & cytokine production256 and it is suggested that 
soluble HS can activate TLR-4257. Integrin-β1 mediates collagens interaction with syndecan-1258 
and other integrins may mediate the interaction between neutrophils and syndecans259. 
Proteolytic cleavage (MMPs, heparanase) or oxidative cleavage of the HS side chains or 
core proteins are two ways that syndecans can transform into soluble effector molecules. 
Heparanase is an endoglycosidic enzyme that cleaves HS side chains260 and is capable of 
cleaving syndecan-1261. Syndecan core protein ectodomains can be shed from the cell surface 
through proteolytic cleavage of the juxtamembrane region (Figure 3). Matrilysin or MMP7 is a 
protease that binds to heparan sulfate262 and induces shedding of the syndecan-1 ectodomain in a 
model of acute lung injury induced by bleomycin263. Consistent with this, MMP-2 and MMP-9 
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can also shed syndecan ectodomains in vitro264. This shedding can be regulated by tissue 
inhibitors of matrix metalloproteinases, such as TIMP-3265. 
Studies also indicate that oxidative fragmentation of HS side chains can occur through 
hypochlorite species generated by MPO161, 163-165 and through hydroxyl radicals generated by 
xanthine oxidase266, 267. This is particularly important in sites of inflammation and neutrophil 
influx. Potential oxidative reactions can occur to the core protein itself or the polysaccharide side 
chains. Protein backbone oxidation is more complex and significant cleavage occurs only with 
very reactive oxygen species such as hydroxyl radicals175. Oxidation and cleavage of the core 
protein can occur through hydrogen abstraction from a central α-carbon and subsequent reaction 
with oxygen to form a peroxyl radical268. This radical can undergo conversion to an α-C alcohol 
and the peptide bond can be cleaved by hydrolysis or to an alkoxyl species resulting in cleavage 
of the peptide bond. Polysaccharide side chain fragmentation can occur through hydrogen 
abstraction from any of the C-H bonds on the sugar residue creating a C-centered radical, called 
an α-hydroxyalkyl radical (.C(OH)RR’)175. This radical can then be converted to a peroxyl 
radical in the presence of oxygen and undergo chain hydrolysis or can undergo β–scission of the 
glycosidic bond which would fragment the chain175, 268. 
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2.0  RATIONALE AND HYPOTHESIS 
2.1 PULMONARY FIBROSIS STUDIES 
Idiopathic pulmonary fibrosis (IPF) is a detrimental lung disease characterized by progressive 
fibrosis of the alveolar interstitium2, 3. Reactive oxygen species (ROS) and markers of oxidative 
stress are evident in human IPF10, 11 and levels of ROS negatively correlate with pulmonary 
function in IPF and may predict disease severity5.  
Extracellular superoxide dismutase (EC-SOD) binds heparan sulfates in the extracellular 
matrix through a matrix binding domain204, 269. EC-SOD protects against the development of 
bleomycin and asbestos-induced pulmonary fibrosis57, 63. Further more, with these injuries EC-
SOD is lost from the alveolar interstitium and collects in the airspaces60.  
In vitro studies, show that heparan sulfate (HS) is susceptible to reactive species such as 
hydroxyl radicals266 and HOCl leading to chain and protein modifications164, 165. Proteolytic 
shedding of syndecan-1, a HS, is involved in bleomycin-induced lung fibrosis263.  
Because matrix proteoglycans are known to be sensitive to oxidative fragmentation and 
EC-SOD is known to bind HS, it is hypothesized that one mechanism through which EC-SOD 
protects the lung from oxidant-induced damage, inflammation, and fibrosis is by preventing 
oxidative fragmentation of heparan sulfate (HS), specifically syndecan-1, in the extracellular 
matrix (ECM). 
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To investigate the relationship of EC-SOD and HS/syndecan-1 in pulmonary fibrosis, a 
human IPF population and two mouse models of pulmonary fibrosis (intratracheal asbestos and 
bleomycin) were utilized in wild type and EC-SOD null (EC-SOD KO) mice. In addition, I 
investigated the effects of shed syndecan-1 ectodomains on neutrophil chemotaxis and alveolar 
epithelial wound healing – both of which are important in the inflammatory and remodeling 
phases of pulmonary fibrosis pathogenesis. 
 
Figure 4: Proposed Interactions of EC-SOD, ROS and Matrix Components. (1) Reactive oxygen 
species (ROS) are generated near the lung epithelium by asbestos fibers or a stimuli; (2) Heparan sulfate side chains 
or core proteins of syndecan-1 are fragmented and released into the extracellular airspace; (3) EC-SOD is localized 
to the cell surface through its matrix binding domain and may prevent fragmentation of matrix components by 
scavenging ROS; (4) If EC-SOD is insufficient, HS or syndecan will be shed by attacking ROS. This may release 
bound factors such as cytokines and EC-SOD from the epithelium. Loss of HS, syndecan and EC-SOD could 
increase tissue susceptibility to oxidative injury and mediate inflammation, wound healing and fibrosis.  
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2.2 CARDIAC FIBROSIS STUDIES 
As an important cardiovascular antioxidant enzyme, EC-SOD has been shown to protect the 
heart from ischemic damage and inflammation177, 229-231. Studies have found that EC-SOD is 
important in the prevention of oxidative injury to the heart that may contribute to cardiac 
remodeling after myocardial infarction and that EC-SOD alters ex vivo heart function229, 230, 232, 
235. Our laboratory has previously found that EC-SOD can protect against pulmonary fibrosis and 
inflammation in mouse models of asbestos and bleomycin-induced lung injury57, 60, 63. In the 
heart, cardiac fibrosis can be modeled utilizing the chemotherapeutic agent, doxorubicin. The 
primary mechanism of doxorubicin-induced myocardial damage involves the generation of 
oxidative stress through quinone-semiquinone reduction-oxidation reactions that produces 
superoxide radicals138. Doxorubicin causes cardiac fibrosis that results in a non-ischemic dilated 
cardiomyopathy and heart failure137, 139, 140. In vitro studies have found that doxorubicin also 
induces myocardial apoptosis138, 270. 
While the role of oxidative stress has been shown in doxorubicin-induced injury to the 
heart, the specific role of EC-SOD in normal cardiac morphology and injury-mediated fibrosis is 
unclear. Thus, we hypothesize that EC-SOD protects the heart from oxidant-induced fibrosis 
and loss of function by mediating inflammation and preventing oxidative ECM shedding.  
To investigate the direct role and functional significance of cardiac EC-SOD in oxidant-
induced inflammation and fibrosis of the heart, a mouse model of doxorubicin-induced cardiac 
injury in wild type and EC-SOD null mice (EC-SOD KO) was utilized. The role of EC-SOD was 
evaluated through functional echocardiography, biochemical and histological assessment of left 
ventricle fibrosis, inflammatory cell infiltration, syndecan-1 fragmentation and apoptosis 
induction. 
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3.0  MATERIALS AND METHODS 
3.1 REACTIVE OXYGEN SPECIES GENERATION 
Reactive oxygen species (ROS) were generated in vitro using a Fenton-like system utilizing 
copper sulfate and hydrogen peroxide (see Figure 1). Variable amounts of 0.1M H2O2 (1.1 – 
2.0mM) and CuSO4 solution, 0.1M NaH2PO4/ 5mM CuSO4 at pH7.4, (working conentrations 0.8 
– 2.0μM CuSO4) were combined to produce superoxide radicals. The amount of superoxide 
produced by the CuSO4/H2O2 system was determined to be 0.068 nmol/min/ml of superoxide at 
1.25 μM CuSO4 using the acetylated cytochrome-c method for detecting superoxide as 
previously described60, 271. For comparison, approximately 0.3 units of xanthine oxidase in a 
xanthine/XO system generated 3 times more superoxide (0.2 nmol/min/ml). 
3.2 ANIMAL STUDIES 
3.2.1 Mice Utilized 
The University of Pittsburgh IACUC approved all animal protocols.  Wild-type C57BL/6 
(Taconic) and EC-SOD-null mice (EC-SOD KO)272 were utilized in studies.  For pulmonary 
models, male mice were used at 8-10 weeks old.  For cardiac models, female mice were used at 
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8-10 weeks old.  Female mice were used because of extreme sensitivity and mortality in the male 
mice due to cardio-toxic agents. This gender sensitivity is commonly seen in cardiac 
experiments. 
3.2.2 Intratracheal Instillation of Fibrotic Stimuli to the Lung 
Mice were weighed daily or every other day throughout the experiments.  C57BL/6 wild type 
and EC-SOD KO mice were treated intratracheally with 0.14 mg sterile crocidolite asbestos 
(NIEHS, Bethesda, MD) or 0.14 mg titanium dioxide (inert control particle, Sigma), as 
previously described 63, 273.  After 1 day, 14 days, and 28 days, mice were euthanized and tissues 
were harvested for analysis, as described below. In select experiments, wild type and EC-SOD 
KO mice were treated with 0.05 Units of bleomycin intratracheally and mice were processed 
after 7 days in the same manner as the asbestos experiments. 
3.2.3 Doxorubicin treatment for Cardiac Fibrosis 
Mice were treated with a single intraperitoneal injection of 15 mg/kg doxorubicin (Adriamycin®, 
Bedford Laboratories, Bedford, OH) or saline on day 0.  The experimental end-point was cardiac 
fibrosis that developed by day 15.  Mice were weighed daily. 
3.2.4 Pulmonary and Cardiac Tissue Harvest and Sample Collection 
For pulmonary experiments, mice were euthanized with 150 mg/kg nembutol intraperitoneally 
and blood samples for serum were collected by cardiac puncture.  Blood was placed into serum 
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separator tubes (BD Microtainer®) to incubate at room temperature for 30 minutes and 
subsequently centrifuged at 12,500 rpm for 6 minutes.  The resulting serums were collected, 
assayed for protein concentrations at a 1:40 dilution using a Bradford Assay (Pierce) and stored 
at -80°C until analysis.   
Bronchoalveolar lavage fluid (BALF) was also collected.  Briefly, the trachea was 
surgically exposed, encircled with suture, and a 24-gauge lavage needle was placed into a 
horizontal cut in the trachea.  The needle was tied down and 800μl of saline was instilled into the 
lungs and recovered.  The lungs were then perfused by cutting the abdominal aorta, and instilling 
8mL sterile saline into the right ventricle of the heart at a 90° angle to the body.  After the lungs 
are perfused to white, they are either removed for hydroxyproline analysis, flash frozen in liquid 
nitrogen for homogenization or RNA isolation, or fixed for histology. Fixation was completed by 
instilling 1.2 mL of 10% buffered formalin into the lavage needle and incubating for 8 minutes.  
Lungs were removed and embedded in cassettes with paraffin.  
For cardiac experiments, mice were first anesthetized with 2.5% Avertin for 
echocardiography, as described below in more detail.  After echo testing, mice were euthanized 
with 150mg/kg nembutol i.p. and blood samples for serum were collected by cardiac puncture to 
the right ventricle and processed as previously described.  The left ventricle of the heart and 
interventricular septum were dissected out, sectioned into separate pieces for protein 
homogenization and RNA isolation, and flash frozen in liquid nitrogen. Weights were collected 
for the LV tissue prior to and after sample sectioning. For histology, whole hearts were weighed, 
perfused/fixed with 10% buffered formalin and paraffin embedded in cassettes. 
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3.3 HUMAN IPF STUDIES 
Human samples from idiopathic pulmonary fibrosis (IPF) and normal lungs were obtained 
(bronchoalveolar lavage fluid (BALF) and paraffin-embedded lung) at the University of 
Pittsburgh or the Clinical Center, National Institutes of Health (NIH), in Bethesda, MD. Written 
informed consent was obtained from subjects seen at the NIH, who were enrolled in protocols 
99-H-0068, 04-H-0211, and/or 04-HG-0211, which were approved by the National Heart, Lung, 
and Blood Institute and the National Human Genome Research Institute Institutional Review 
Boards. Tissue samples for lung homogenates were obtained through the University of 
Pittsburgh Health Sciences Tissue Bank, as previously described274.  Nine samples were obtained 
from surgical remnants of biopsies or lungs explanted from patients with IPF who underwent 
pulmonary transplant and control normal lung tissues obtained from the disease free margins 
with normal histology of lung cancer resection specimens.  The morphologic diagnosis of IPF 
was based on typical microscopic findings consistent with usual interstitial pneumonia.  All 
patients fulfilled the diagnostic criteria for IPF outlined by the American Thoracic Society and 
European Respiratory Society 3, 4.  The use of all samples was approved by the Institutional 
Review Board at the University of Pittsburgh. The homogenization process was the same as used 
for mouse lung samples described in 3.5.2.  For immunohistochemistry, see the section 3.6.  
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3.4 CARDIAC FUNCTION ANALYSIS 
3.4.1 Echocardiography and Functional Calculations 
Echocardiography was completed using a Visual Sonics machine with a 25-MHz transducer, as 
previously described275, 276.  Mice were anesthetized with 2.5% wt/vol Avertin at 8.5 μL/g body 
weight by intraperitoneal injection.  Parasternal short axis B-mode and M-mode images and heart 
rate were collected (Figure 5).  Measurements were performed on 5 complete beats and 
averaged.  Left ventricular end diastolic dimension (LVEDD; mm) and posterior wall thickness 
(LVPWT, mm) were determined at maximal ventricular relaxation and LV end systolic 
dimension (LVESD; mm) was determined at maximal posterior-wall motion.   
The relative posterior wall thickness is a ratio of LVEDD / LVPWT, as previously 
described 277.  Heart rate (bpm, beats per minute) was determined from 5 consecutive full wave 
intervals.  The percentage of fractional shortening and ejection fraction were calculated using the 
following equations from measurements taken on M-mode images: 
Fractional Shortening % = ((LVEDD – LVESD) / LVEDD) x 100 
Left ventricular volume LV volume, μl:  
 LV Voldiastolic = (7 / (2.4 + LVEDD)) x LVEDD3 x 1000 
LV Vol systolic = (7 / (2.4 + LVESD)) x LVESD3 x 1000 
Ejection Fraction % = ((LV Vol diastolic – LV Vol systolic) / LV Vol diastolic ) x 100 
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A.  
B.  
Figure 5: Images and measurements of the Left Ventricle of the Heart. A) B-mode image with LV 
within the highlighted area. Images were collected in the middle of the left ventricle just below the papillary 
muscles. B) M-mode image (LV cross-section) containing 3 measurements: left ventricular end diastolic dimension 
(LVEDD; mm) and posterior wall thickness (LVPWT, mm) were determined at maximal ventricular relaxation and 
LV end systolic dimension (LVESD; mm) was determined at maximal posterior-wall motion. 
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3.5 BIOCHEMICAL ANALYSIS 
3.5.1 Bronchoalveolar lavage analysis 
Bronchoalveolar lavage fluid (BALF) total cell counts were determined using a Bechman 
Coulture Counter.  Cytospins slides were created using 50μl of BALF (Cytospin machine) and 
50μl 50mM Tris-HCl.  Slides were dried for 24 hours, stained with Diff Quick Cellular Stain 
(Dade Behring, Newark, DE), and cover-slipped using Peramount mounting media (Sigma).  
Cell differentials were determined by counting 200 total cells/slide (including neutrophils, 
macrophages, eosinophils/basophils, and lymphocytes) at 40X magnification using bright field. 
The evaluator was blinded to all sample groups.  
3.5.2 Lung and Heart Homogenization 
Frozen excised lung and dissected left ventricular tissue were homogenized on ice in 
homogenization buffer (50 mmol/L potassium phosphate, pH 7.4, 0.3 mol/L potassium bromide) 
with protease inhibitors (10μmol/L Dichloro-isocoumarin and 100μmol/L E-64 (L-
transepoxysuccinyl-leucylamido-[4-guanidino]butane), Sigma) and sonicated.  The samples were 
centrifuged at 20,000 g for 20 minutes at 4°C.  The supernatant was collected as the soluble LV 
fraction and stored at -80°C until use.  Two volumes of CHAPS detergent (50 mmol/L Tris-HCl, 
pH 7.4, 150 mmol/L NaCl, 10 mmol/L CHAPS) with the same protease inhibitors, were used to 
re-suspend the pellet.  The samples were rotated for 2 hours at 4°C followed by sonication and 
centrifuged. The supernatants were collected as the membrane protein fraction and stored at -
80°C until use.   
  48
3.5.3 Western Blot Analysis 
Serum, human and mouse BALF and lung homogenate samples, and mouse left ventricular (LV) 
homogenate protein concentrations were determined by a Bradford assay (Pierce). Samples were 
separated by SDS-PAGE and transferred to PVDF membranes123 and probed for proteins of 
interest. Membranes were probed for EC-SOD (rabbit anti-mouse or rabbit anti-human EC-SOD 
antibody)278, heparan sulfate proteoglycan HSPG (MAB2040), syndecan-1 ectodomain (rat anti-
mouse syndecan-1 antibody 1μg/ml, clone 281.2 BD Biosciences), syndecan-4 (1μg/ml, clone 
KY8.2, BD Biosciences), mouse anti-human syndecan-1 (B-A38, Diaclone, Besancon, France) 
for human lung samples, or caspase-3 (anti-mouse caspase-3, recognizes 37kDa pro-form and 
12-17kDa active form), then a Horseradish Peroxidase (HRP)-conjugated donkey anti-rabbit IgG 
or goat anti-rat IgG secondary antibodies (Jackson ImmunoResearch, West Grove, PA). ECL 
detection reagents were used for visualization (ECL-plus, GE Healthcare). Ponceau red was used 
to normalize BALF samples and coomassie blue membrane staining or β–actin densitometry was 
used to normalize homogenates and serum for protein loading.  Images were captured with a Gel 
Logic 2200 system (Kodak) for densitometry (mean normalized net intensities ± SEM). 
To confirm extracellular oxidative stress in the doxorubicin heart experiment, LV 
homogenates were assayed using an Oxyblot Kit (Chemicon). Briefly, this kit detects carbonyl 
groups which are a marker of oxidative modification of proteins. Equal amounts of protein were 
derivatized to 2,4-dinitrophenylhydrazone by reacting each with dinitrophenylhydrazine 
(DNPH). Non-derivatized samples were used as assay controls. Samples were separated by SDS-
PAGE and transferred to a PVDF membrane.  The membrane was probed with an antibody 
against DNP, according to the manufacturers instructions. 
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3.5.4 Hydroxyproline Assay 
Whole lungs (right and left sides) or cardiac left ventricle tissue were dried in glass vacuoles in a 
110°C oven for 48 hours and then dry weights were collected. Acid hydrolysis of each sample 
was completed by adding 2 ml of 6M HCl and oxygen from each vial was replaced by nitrogen 
gas under vacuum.  Vials were sealed and incubated for 24 hours at 110°C, dried and assayed for 
hydroxyproline content using chloramine-T, as previously described 279.   
Briefly, the hydroxyproline standard curve (0-5μg/ml) was created using 10μg/ml trans-
4-Hydroxy-L-proline in PBS.  Standards and acid-hydrolyzed samples were incubated with 
chloramine-T solution for 20 minutes at room temperature and subsequently incubated with 
3.15M perchloric acid for 5 minutes.  To each sample, p-dimethylaminobenzaldehyde solution 
was added and incubated for 20 minutes at 60°C for color development and read in a 96-well 
plate at 557nm on a spectrophotometer (SpectraMax plus, Molecular Devices, Sunnyvale, CA) to 
obtain the hydroxyproline concentrations. 
3.5.5 RNA Isolation and Quantitative reverse transcriptase polymerase chain reaction 
RT PCR was used to determine mRNA expression (ddCt relative quantification) of EC-SOD 
from wild-type mice and syndecan-1, MMP2, MMP7, and MMP9 from wild type and EC-SOD 
KO mice.  All reagents were purchased from Applied Biosystems (Foster City, CA) unless 
noted.  RT reactions were performed as previously described 278, 280, using 1μg of RNA isolated 
from lung and left ventricular tissue using an RNeasy kit (Qiagen) and 5 mmol/L MgCl2, PCR 
buffer II, 1 mmol/L nucleotide mix (Promega, Madison, WI), 1.0 U RNAsin (RNase Inhibitor), 
2.5 U MuLV reverse transcriptase enzyme, and 3µg of random hexamers.  Reactions were 
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performed on a Techne thermocycler (MIDSCI, St. Louis. MO) programmed for 42°C for 40 
minutes, 99°C for 5 minutes, and 5°C for 5 minutes. 
Quantitative PCR was performed by adding Universal PCR buffer and primer/probe assay 
reagents for EC-SOD, syndecan-1, MMP2, MMP7 and MMP9 (EC-SOD: Mm00448831_s1; 
syndecan-1: Mm00448918_m1 Sdc1, MMP2: Mm00439506_m1; MMP7:  Mm01168420_m1; 
MMP9: Mm00442991_m1, Applied Biosystems) according to the manufacturer’s protocol.  
GAPDH was used for sample normalization and loading control.  An ABI Prism 7300 (Applied 
Biosystems, Foster City, CA) was used to run the default program (50°C for 2 minutes, 95°C for 
10 minutes, and 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute).  Sequence Detection 
Software Version 1.4 (Applied Biosystems) was used to analyze the data based on the crossing 
threshold and to obtain mRNA expression relative quantities for each sample.  The ddCt relative 
expressions for the treatment groups were averaged and the expression of the control group was 
set to 100%.  Data are reported as relative percent ddCT expression versus control, n=5 samples 
per group, per gene (mean ± SEM). 
3.6 HISTOLOGICAL ANALYSIS 
3.6.1 Hematoxylin and Eosin histology staining 
Mouse lungs or hearts were fixed with 10% buffered formalin and paraffin embedded. 4μm thick 
sections of tissue were placed on to slides and heated at 60°C overnight, deparaffinized with 
xylene, rehydrated with an ethanol series, and stained with Hematoxylin and Eosin then cover-
slipped with Permount mounting fluid. H&E sections of the heart were imaged at 2X 
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magnification on a macro-dissecting scope (Olympus America Inc., Center Valley, PA) and lung 
H&E sections were imaged using bright field at 40X magnification on an Olympus IX7 
microscope (Olympus, Center Valley, PA).  
3.6.2 Picro-Sirius Red Staining 
Sirius red staining was completed similarly to that previously described281, 282. Briefly, nuclei 
were stained for 1 minute with Weigert’s hematoxylin, washed with distilled water for 5 minutes, 
then stained for 1 hours in 0.1% Sirius red stain (Direct Red 80, Sigma) in saturated picric acid.  
Slides were washed twice in acidified water (5% acetic acid), dehydrated with an ethanol series, 
and cleared with xylene.  Sections were cover-slipped and mounted with Peramount (Sigma).  
This stain identifies collagen fibers by staining them orange/red. Fibers can also be seen using 
polarized light, which results in collagen fibers visualized as yellow/green. 
3.6.3 Masson’s Trichrome Staining 
This stain is used to detect the presence of collagen within tissue.  Collagen stains blue, nuclei 
stain dark brown and cytoplasms and backgrounds stain red. Staining was completed by 
Histological Services at the University of Pittsburgh. 
3.6.4 TUNEL Straining 
Using the TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end 
labeling) method, cardiac sections were stained for the detection of fragmented DNA, which is 
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indicative of apoptotic cells. Sections were incubated with TdT-reaction solution and nuclei were 
visualized with streptavidin-rodamine labeled fluorescence using a TUNEL kit (Promega, 
Madison, WI) and DAPI (4′,6 diamidino-2-phenylindole, dihydrochloride) nuclear stain. 
Conventional fluorescence images were obtained by using a Nikon Microphot-FXA fluorescence 
microscope (Nikon Instruments, Inc, Melville, NY), as previously described283. 
3.6.5 Immuno-fluorescent histochemistry 
3.6.5.1 Lung IHC 
Mouse lungs were inflation fixed with 10% buffered formalin for 4 hours and embedded in 
paraffin. Fixed and embedded human control and IPF lung samples were also used.  Sections 
were cut at 5μm and were adhered to slides for 30 minutes to overnight at 60ºC followed by 
deparaffinizing with xylene and rehydration in an ethanol series.  The sections were treated with 
sodium citrate buffer at 95ºC for antigen retrieval.  Human and mouse lung sections were stained 
for colocalization with antibodies specific to syndecan-1 (human: .2μg/ml, B-A38, Abcam, 
Cambridge, MA; mouse: 1μg/ml, 281.2, BD Bioscience) and EC-SOD (1:500, generated as 
described below) and secondary antibodies labeled with Cy3 and Alexa 488 (1:500, Jackson 
immunoresearch, Westgrove, PA). Stained sections were imaged at 40X using an Olympus IX7 
microscope (Olympus, Center Valley, PA). Control sections were stained with non-immune 
mouse IgG and pre-immune serum (AnaSpec). Areas of fibrosis were confirmed with H&E 
staining of serial lung sections by a board certified pathologist (T.D.O.). 
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3.6.5.2 Heart IHC 
Mouse hearts were fixed with 10% buffered formalin overnight at 4ºC and embedded in paraffin. 
Sections were cut at 4μm and were adhered to slides for 30 minutes to overnight at 60ºC 
followed by deparaffinizing with xylene and rehydration in an ethanol series. The sections were 
treated with sodium citrate buffer at 95ºC for antigen retrieval. Sections were stained with an 
anti-mouse CD45 antibody (1μg/ml, ab25386, Abcam, Cambridge, MA) and a secondary 
antibody labeled with Cy3 (1:5000, Jackson immunoresearch, Westgrove, PA). Hoecht stain was 
used for nuclear localization. Stained sections were imaged at 40X using an Olympus IX7 
microscope (Olympus, Center Valley, PA).  Control sections were stained with non-immune 
mouse IgG.  
3.7 PURIFICATION OF HUMAN EC-SOD 
EC-SOD was purified from human aorta (84g total), as previously described with minor 
modifications200, and homogenized in 800ml of homogenization buffer (50mM KPO4, 0.3M KBr 
pH 7.4) with protease inhibitors (0.5mM PMSF, 0.01 m ME-64 and 0.1mM orthophenantholine). 
The homogenate was centrifuged and run over a Con-A column. Proteins bound to the column 
were eluted with elution buffer (50mM HEPES pH 7, 0.25M NaCl, 200mM methyl a-
mannopyranoside). The eluted protein was dialyzed and loaded onto a heparin-sepharose 
column. Fast protein liquid chromatography was completed on the eluted EC-SOD fractions, as 
previously described. Pooled fractions were run on a mono-Q sepharose column and fractions 
analyzed by FPLC. Pooled fractions of purified EC-SOD were run over an AffinityPak 
DetoxiGel Column (Thermo-Fisher) to remove endotoxin. The final endotoxin level in the 
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purified EC-SOD was less than 0.2 EU/mg using a Limulus Amebocyte Lysate assay according 
to the manufacturers protocol (Cape Cod Inc., Falmouth, MA). The EC-SOD activity was 3,374 
U/ml and was determined utilizing the acetylated cytochrome-c method, as previously 
described271. 
3.8 GENERATION OF EC-SOD ANTIBODIES 
Mouse and human EC-SOD specific polyclonal antibodies were generated by immunizing 
rabbits with a Keyhole Limpet Hemocyanin (KLH) conjugated peptide containing either the first 
19 amino acids in mouse EC-SOD and an additional cysteine residue at position 20 
(SSFDLADRLDPVEKIDRLDC) or a peptide containing human EC-SOD amino acid residues 
19-37 and an additional cysteine residue in position 20 (WTGEDSAEPNSDSAEWIRDC) by 
AnaSpec Corporation (San Jose, CA).  Antiserums containing the EC-SOD antibodies were 
collected at the time of sacrifice 2 weeks after the second boost.  Titers against the peptide were 
performed to confirm immunogenicity.  Antibody specificity for EC-SOD was confirmed by the 
detection on Western Blot analysis of lung homogenate.  Pre-immune serum was also collected 
to obtain control IgG. 
3.9 SYNDECAN SPECIES UTILIZED 
A Glutathione-S-Transferase (GST)-human syndecan-1 ectodomain fusion protein (hS1ED) was 
used in cell experiments at concentrations between 500ng/ml and 1 μg/ml (provided by Dr. Alan 
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Rapraeger and purified as previously described284).  The present studies focus on the functions of 
the ectodomain protein itself, as there are no glycosaminoglycan chains present on the protein. In 
addition, a peptide was synthesized from 20 amino acids of the syndecan-1 ectodomain, syn 
peptide (95.2% purity, GenScript Corporation, Piscataway, NJ). Region aa11-30 include 2 of 4 
glycosaminoglycan (GAG) side chain attachment sites and are composed of serine-glycine 
repeats. Figure 35A shows the peptide. 
3.10 HEPARIN AND HEPARAN SULFATE FRAGMENTATION ANALYSIS 
For evaluation of GAG chain oxidative fragmentation, heparin and heparan sulfate were 
incubated with reactive oxygen species as described in section 3.1. Reactions were immediately 
vortexed and incubated for 2 hours at room temperature on a rocker. Samples were separated by 
electrophoresis on 15% polyacrylamide gels. The gels were stained overnight in StainsAll 
(Sigma), which binds polyanionic carbohydrate species, and photo-destained.  
3.11 CELLULAR CHEMOTAXIS ASSAY 
A neutrophil chemotaxis assay, consisting of a modified Boyden chamber, as previously 
described285, as shown in the image below. The assay was used to evaluate the migration of 
primary human neutrophils (PMNs) in response to oxidatively shed syndecan-1 in A549 cell 
supernatants (step 1 of the following image) or to syndecan-1 peptide (50 ng/ml to 1 μg/ml, 
Abcam, Cambridge, MA) or heparan sulfate proteoglycan, (HSPG; 6 μg/mL, Sigma) treated with 
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reactive oxygen species (ROS) (step 2 of the following image). In select experiments the effect 
of EC-SOD was investigated. HSPG was treated with ROS in the absence or presence of 5-100 
units of human EC-SOD, purified from human aorta, as previously described200, or CuZn SOD 
(Bovine liver, Alexis, San Diego, CA).  
 
In brief, human neutrophils (PMNs) were isolated using dextran and Ficol gradient 
sedimentation, as previously described259.  PMNs (2x106) were added to the upper chamber of 
transwell inserts (5 μm pore size, Corning Inc., Corning, NY) in a 24-well plate. The lower 
chambers contained Hanks Balanced Salt Solution (HBSS, Sigma) with the appropriate 
treatments indicated in the figures. 
For select experiments, A549 cell monolayers were treated media, control siRNA or 
syndecan-1 siRNA for 24 hours then treated with HBSS or ROS for 2 hours at 37ºC/5% CO2. 
Cell supernatants were collected and applied to the lower chamber of the chemotaxis assay with 
neutrophils added to the upper chamber as described above.  ROS were generated in sterile 
HBSS using a CuSO4/ H2O2 system as previously described151, 186, 273. The chemotaxis chambers 
were incubated for 2 hrs at 37ºC/5% CO2.  Cell counts were completed on lower chamber 
supernatants on a Beckmann Coulter Counter (Beckmann Coulter, Fullerton, CA). A neutrophil 
migration index was calculated286 as follows:  (Migrated cells to treatment/ randomly migrated 
cells (HBSS)).  An index greater than 1 represents chemotaxis (mean ± SEM). 
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3.12 CELL CULTURE 
3.12.1 Primary mouse epithelial cell culture and epithelial cell lines 
Primary mouse epithelial cells were harvested and cultured from C57BL-6 mice, as previously 
described287 and grown on collagen IV coated 24-well plates for experiments. Briefly, cells were 
isolated from from 6-week-old female C57BL/6 mice by a method of Rice et al.  Mice were 
anesthetized with 200μl i.p. Nembutal. The chest and abdominal cavities were exposed and the 
trachea was exposed and cannulated with a 20-gauge luer-stub adapter. The anterior ribs were 
removed to expose the heart and lungs and the abdominal aorta was severed. The lungs were 
perfused with 10ml 0.9% saline by inserting a 21-gauge needle on a 10-ml syringe in to the right 
ventricle at a 90° angle. Dispase (3 ml) was instilled through the tracheal cannula followed 
immediately by 0.5 ml low melt agarose at 45°C. Lungs were immediately covered with ice for 
2 min to gel the agarose. After this incubation, lungs were removed and incubated in 1 ml dispase 
for 45 min at 25°C. Lungs were subsequently transferred to a 60-mm culture dish containing 
7 ml of HEPES-buffered DMEM and 100 U/ml DNAse I. Lung tissue was gently teased apart 
and the cell suspension was filtered through progressively smaller cell strainers (100 and 40 µm) 
and nylon gauze (20 µm). Cells were collected by centrifugation at 130 g for 8 min (4°C) and 
placed on prewashed/antibody pre-coated 100-mm tissue culture plates (coated for 24-48 h at 
4°C with 42 µg CD45 and 16 µg CD32 in PBS). After incubation for 1-2 h at 37°C, type II cells 
were gently panned from the plate and collected by centrifugation.  
Type II cells were resuspended in culture media and cultured on collagen IV coated 
plates. The media was changed after the 1st day of culture. By day 7, the cells have differentiated 
from type II into type I alveolar epithelial cells.  The approximate cell yield for this isolation 
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protocol is 4 to 6 × 106 cells/mouse. The purity of type II cell preparations was typically >90% 
and assessed by modified PAP stain287, 288 on cytospin slides. PAP stain, a modified 
Papanicolaou stain, enables the visualization of cellular inclusions of type II alveolar cells 
(Figure 32). Briefly, 2x105 cells were cytospun onto slides and dried.  Slides were incubated in 
hematoxylin solution for 3 minutes, swished in distilled water, incubated in lithium carbonate 
(1:1000 of saturated solution) for 2 minutes.  Slides were rinsed with water, incubated in 70% 
ethanol for 1.5 minutes, 80% ethanol for 15 seconds, 95% ethanol for 15 seconds, 100% ethanol 
for 30 seconds, and xylene for 1 minute.   
A549, alveolar epithelial cells (ATCC), were grown on 24-well plates with DMEM plus 
10% fetal bovine serum for experiments. Cells were serum starved for 18-24 hours prior to 
experiments. 
3.12.2 Fibroblasts studies 
A human lung fibroblast cell line, LL47 (ATCC), was grown on 6-well plates with F12K 
medium plus 10% fetal calf serum for experiments. LL47 fibroblasts were plated on 96 well 
plates (4,000 cells/well) and placed in serum free F12K media 24 hours prior to treatment.  Cells 
were treated with media or 1 μg/ml human syndecan-1 ectodomain (hS1ED) for 24 hours at 
37ºC/5% CO2.  Fibroblast proliferation was determined over 2 hours using CellTiter 96 AQ Non-
Radioactive Assay at 333μg/ml MTS and 25 μM PMS (Promega, Madison, WI).  Absorbance at 
490 nm, which is proportional to the number of metabolically active cells, was recorded on a 
plate reader and reported as mean ± SEM, n=8.  LL47s were also cultured to confluency on 12 
well polystyrene plates, placed in serum free media for 24 hours, and treated with 1 μg/ml 
hS1ED for 48 hours.  Supernatants were collected and assayed by ELISA for latent and active 
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TGF-ß1 (R&D Systems, Minneapolis, MN).  For α-smooth muscle actin (α-SMA) detection, 
fibroblast cell lysates were collected in ice-cold cell lysis buffer with protease inhibitors and 
separated on SDS page.  After transfer to a membrane, mouse anti-α-SMA primary antibody 
(Sigma) was used for detection and normalized to β-actin as described. 
3.12.3 siRNA Treatment 
For select experiments, A549 cell monolayers were treated with media, human syndecan-1 
siRNA (sc-36587, Santa Cruz) or negative control siRNA (#AM4611, Ambion) 24 hours prior to 
ROS treatment in order to knockdown cell surface syndecan-1 expression. The syndecan-1 
siRNA is a pool of 3 separate siRNA that individually specifically target syndecan-1 expression. 
The optimal siRNA concentration was determined at 30 and 60 µM.  A concentration of 30 µM 
was used for all additional experiments along with Lipofectamine 2000 (Invitrogen) and Opti-
mem I (Gibco) reagents according to the manufacturer’s protocol.  For neutrophil chemotaxis 
experiments, A549 cells were treated with siRNA and controls for 24 hours then treated with 
HBSS or ROS for 2 hours at 37ºC/5% CO2.  Cell supernatants were collected and applied to the 
lower chamber of the chemotaxis assay. For wound healing experiments, A549s were treated 
with siRNAs and wounds were created 24 hours after siRNA treatment. hS1ED (1μg/ml) was 
added immediately after the wound was created and washed, as described in section 3.3. 
3.12.4 Syndecan-1 Shedding Assays 
For shedding assays, A549s were exposed to ROS and EC-SOD for 30 minutes at 37ºC/5% CO2. 
Cells were fluorescently labeled for syndecan-1, as previously described265, and supernatants 
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were analyzed for shed syndecan-1 ectodomain by dot blot. Samples were applied to PVDF 
membranes using a dot blot apparatus. The membrane and filter papers were pre-soaked in 
transfer buffer. Samples were applied and suctioned through onto the membrane, which was then 
incubated in 5% dry milk in PBS-tween overnight at 4ºC. The membrane was probed for 
syndecan-1 ectodomain, as described in section 3.5.3.  
3.13 EPITHELIAL WOUND HEALING ASSAY 
For wound assays, primary mouse alveolar epithelial cells or A549 cells were grown to 
confluency in 24 well collagen IV-coated culture plates with growth media. (primary cells: 
DMEM with 10% fetal bovine serum and antibiotics; A549s: F12K media with 10% FBS; 
Invitrogen, Carlsbad, CA).  Straight wounds were created with a p-200 pipet tip289.  Wounds 
were washed and treated with syndecan-1 (hS1ED).  Wound images were captured using a 4x 
objective with phase contrast at time 0 and 18 hours or 24 hours.  Metamorph software 
(Molecular Devices, Downingtown, PA) was used to determine wound areas.  The measurement 
tools were calibrated for the objective lens used.  Percent wound healing was calculated with the 
following equation:  (Wound Area (initial)- Wound Area(final) /Wound area(initial) )x100.  
For select experiments, primary AECs were treated with 9.5μg/ml crocidolite asbestos 
immediately after monolayers were wounded and washed. Asbestos was suspended at 1mg/ml in 
sterile media, sonicated and run through a 22 gauge needle prior to treatment of cells. Wounds 
were assessed at 24 and 48 hours. 
  61
4.0  STATISTICAL ANALYSIS 
Mean densitometry and all other quantitative data (mean ± SEM) were assessed for significance 
using the Student’s t-test or ANOVA (one or two-way determined by the experiment parameters) 
followed by Tukey’s post-test using Graphpad Prism software (Graphpad, San Diego, CA).  
Significance was achieved by a p-value < 0.05.  Sample sizes (n) are indicated in the figure 
legends. 
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5.0  RESULTS – PULMONARY FIBROSIS 
5.1 ASBESTOS AND BLEOMYCIN INJURY INDUCE HEPARAN SULFATE AND 
SYNDECAN SHEDDING 
 
To investigate heparan sulfate (HS) shedding in pulmonary fibrosis and oxidative injury, we 
utilized wild type (WT) and EC-SOD KO mice that were treated with asbestos or bleomycin and 
bronchoalveolar lavage fluid (BALF) was collected at various timepoints. HS was evaluated by 
western blot analysis. EC-SOD KO mice are more susceptible to oxidative damage and lung 
fibrosis57, 63. At 24 hours post-asbestos exposure, shed HS significantly increases in the BALF of 
WT mice (Figure 6A). Furthermore, EC-SOD KO mice have significantly more shed HS species 
in their BALF at 24 hours, 14 and 28 days post-asbestos exposure. By molecular mass, we 
predict that HS2 is syndecan-1 and that HS3 is syndecan-4.  
To verify that the pulmonary epithelium expresses syndecan-1 and syndecan-4 species, 
primary mouse alveolar epithelial cells were isolated and stained for syndecan-1 or syndecan-4 
in vitro. Figure 7 shows punctate clusters of syndecan-1 on the cell surface of the AECs and a 
more diffuse expression for syndecan-4 with some areas of clustering on the cell borders and 
sites of adhesion. 
 Figure 6: Heparan sulfate proteoglycans (HSPG) are shed into the BALF during asbestos induced 
injury. EC-SOD KO mice and wild type mice were exposed to asbestos and HSPG levels in the BALF were 
analyzed by western blot (antibody MAB2040) and were normalized to ponceau red and reported as mean ± SEM. 
The various detected species are labeled HS1, HS2, HS3. *, p<0.05 A) Wild type mice after 24 hours asbestos 
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exposure; B) 24 hours post-asbestos exposure; C) 14 days post-asbestos exposure; D) 28 days post-asbestos 
exposure. 
 
Figure 7: Syndecan expression in Primary Alveolar Epithelial Cells (AECs). Primary AECs were 
isolated from C57BL/6 mice and cultured. Cells were stained for cell surface syndecan-1 or syndecan-4. Images are 
representative of multiple wells of stained cells. A non-immune IgG antibody was used as the primary antibody for 
the control cells. 
To confirm the identity of the shed HS species, BALF samples were analyzed for the 
shed ectodomains of the syndecan-1 and syndecan-4 core proteins. After asbestos injury, levels 
of shed syndecan-1 are significantly increased in the BALF of WT mice at 1 day, 14 and 28 days 
post-exposure (Figure 8A-C, n=5). Additional significant increases in shed syndecan-1 were seen 
in asbestos-treated EC-SOD KO mice at the 1 day and 28 day time points compared to WT 
asbestos mice (Figure 8A and C). Initial studies show that titanium dioxide (control particulate) 
does not induce heparan sulfate or syndecan shedding into the BALF in wild type nor EC-SOD 
KO mice. To keep animal numbers to a minimum, the titanium dioxide control was not included 
for the EC-SOD KO strain for every time point and experiment. 
In a second model of pulmonary fibrosis, bleomycin injury caused a significant increase 
in shed syndecan-1 in the BALF of EC-SOD KO mice when compared to WT mice at day 7 after 
bleomycin treatment (Figure 8D). Syndecan-1 cell surface expression also increases by day 28 in 
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tissue homogenates of asbestos-exposed EC-SOD KO mice, with the trend beginning at 14 days 
post-exposure (Figure 9). These findings suggest that syndecan-1 is sensitive to oxidative 
shedding during the inflammatory (1 day time point) and fibrotic (7-28 day time points) phases 
of pulmonary fibrosis and that syndecan-1 cell surface expression increases with fibrosis 
development. 
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 Figure 8: Syndecan-1 ectodomain is shed into the BALF during pulmonary fibrosis. The syndecan-1 
ectodomain protein was detected in BALF samples using western blot analysis with normalization to ponceau red 
and reported as mean ± SEM. A) 24 hours post-asbestos exposure; B) 14 days post-asbestos exposure; C) 28 days 
post-asbestos exposure; D) 7 days post-Bleomycin exposure. *,p<0.05. 
 
  67
 Figure 9: Syndecan-1 changes in lung homogenates after asbestos exposure. Syndecan-1 in lung 
homogenates was determined by western blot at A) 14 days post-asbestos exposure and B) 28 days post-asbestos, *, 
p<0.05, n=3-5; A significant increase in syndecan-1 protein expression is seen at 28days in the EC-SOD KO mice 
compared to WT.  
Syndecan-4 is also sensitive to oxidative shedding in the lung. BALF was analyzed by 
western blot analysis for the syndecan-4 ectodomain of the core protein. At day 1 and 28 post-
asbestos exposure, shed syndecan-4 was significantly increased in the BALF of asbestos-treated 
EC-SOD KO mice compared to asbestos WT mice (Figure 10A, C). Syndecan-4 levels were 
significantly elevated in asbestos-treated WT mice only at the 14 day time point (Figure 10B). 
Similar to syndecan-1 in the bleomycin fibrosis model, syndecan-4 shedding is also increased in 
BALF of EC-SOD KO at day 7 after bleomycin (Figure 10D). There is a trend toward increased 
syndecan-4 cell surface expression in tissue homogenates by day 28 post-asbestos exposure 
(Figure 11).  
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 Figure 10: Syndecan-4 ectodomain is shed into the BALF during pulmonary fibrosis. The syndecan-4 
ectodomain protein was detected in BALF samples using western blot analysis with normalization to ponceau red 
and reported as mean ± SEM. A) 24 hours post-asbestos exposure; B) 14 days post-asbestos exposure; C) 28 days 
post-asbestos exposure; D) 7 days post-Bleomycin exposure. *, p<0.05. 
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 Figure 11: Syndecan-4 trends toward increased expression in lung homogenates after asbestos. 
Syndecan-4 in lung homogenates was determined by western blot at 28 days post-asbestos, n=3-5. 
5.2 SYNDECAN SHEDDING IN HUMAN IDIOPATHIC PULMONARY FIBROSIS 
To investigate if syndecan shedding also occurs in subjects affected with Idiopathic pulmonary 
fibrosis (IPF), we measured syndecan-1 and syndecan-4 levels by western blot analysis in BALF 
and lung homogenates from patients who met ATS/ERS criteria for sporadic IPF4. The patient 
population studied includes normal control volunteers with an average age of 49 ± 15, 60% male 
and  >90% Caucasian. The average age of the IPF patient population was 66 yo ± 9, 87% male 
and >90% Caucasian. Pulmonary function testing shows a restrictive pattern in the IPF patients, 
as well as, abnormal diffusion capacity of the lung for carbon monoxide (DLCO) (Figure 12A, 
Personal communication & permission from Ivan Rosas, M.D.). A decrease in percent predicted 
DLCO, as apperent in this IPF population, suggests thickening of the alveolar interstitium and 
decreased alveolar gas exchange. Cellular analysis of BALF samples show that the IPF patients 
have significant increases in total cell counts, neutrophils, and eosinophils (Figure 12B,*p<0.05).  
  70
A  
B
 
Figure 12: IPF and normal volunteer pulmonary function and BALF characteristics. The diffusion 
capacity of the lung for carbon monoxide (DLCO) was determined. A) DLCO percent of the predicted value; B) 
Total BALF cell counts, percent neutrophils, and percent eosinophils in BALF were determined from normal 
volunteers and IPF patients (personal communication & permission from Ivan Rosas, M.D.). 
Shed syndecan-1 ectodomains in BALF samples from the normal volunteers and IPF 
patients were analyzed by western blot. Patients with sporadic IPF have significant increases in 
shed syndecan-1 in their BALF (p<0.01, Figure 13A) and lung homogenates (p<0.05, Figure 
13B) compared to normal controls.  
Syndecan-4 levels were also significantly increased in the BALF (p<0.05, Figure 14A) 
and lung homogenates (p<0.05, Figure 14B) of IPF patients compared to controls. 
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 Figure 13: Increased syndecan-1 ectodomain in the BALF and lung of IPF patients. Syndecan-1 was 
detected by western blot analysis and presented as normalized net intensity. Protein loading was standardized by 
ponceau red stain for BALF samples and β-actin for lung homogenates (mean ± SEM). Increased syndecan-1 in A) 
BALF samples, *, p<0.05, n=5 and B) lung homogenate samples, *, p<0.05, n=4 or 5. 
 
Figure 14: Increased syndecan-4 in BALF and lung in IPF patients. Syndecan-4 was detected by 
western blot analysis and presented as normalized net intensity. Protein loading was standardized by ponceau red 
stain for BALF samples and β-actin for lung homogenates (mean ± SEM). Increased syndecan-4 in A) BALF 
samples, *, p<0.05, n=5 and B) lung homogenate samples, *, p<0.05, n=4 or 5. 
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IPF disease progression can be classified by disease severity stages based on pulmonary 
function testing: mild, moderate and severe IPF. Syndecan-1 levels in BALF samples were 
quantified by ELISA. IPF patients at all disease severity stages show increases in the levels of 
shed syndecan-1 in BALF samples (Figure 15). Syndecan-1 levels are lower in the cases of 
severe IPF, which may be due to lung burnout where the fibrosis and collagen deposition has 
encompassed much of the alveolar epithelium creating lower cell numbers and syndecan-1 
levels.  
 
 
Figure 15: Levels of BALF Syndecan-1 increase with all stages of IPF disease severity. BALF samples 
from normal volunteers and IPF at mild, moderate and severe IPF stages were assayed for syndecan-1 using a 
CD138 (Syn-1) ELISA kit. Samples were assayed in triplicate and data are reported as mean ± SEM for each 
sample, *p<0.05, n=8 per disease stage. Disease stages were clinically determined by lung function testing and 
DLCO. 
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5.3 FIBROTIC LUNG INJURY MODULATES EC-SOD AND SYNDECAN-1 
DISTRIBUTION IN THE LUNG. 
To further investigate syndecan-1 and EC-SOD expression in the lung in reponse to pulmonary 
fibrosis, H&E staining and immunofluorescent staining for syndecan-1 and EC-SOD were 
performed on human and mouse lungs with and without fibrosis. H&E staining confirmed the 
presence of fibrosis in human lungs with IPF (Figure 16). IPF lungs show heterogeneous fibrosis 
with areas of thickened alveolar septae and increased collagen deposition (Figure 16 B, D). 
Classic histological findings in IPF lungs were observed including myofibroblastic foci (Figure 
17), which are considered to be active areas of inflammation and progressive fibrosis. 
 
Figure 16: H&E staining of control and IPF lung. Control and IPF lung sections (4μm) were stained 
with H&E. A) Control human lung at 20X; B) Control lung at 40X depicting thin alveolar septae; C) IPF lung at 
20X magnification showing thickening of the interstitium; D) IPF lung at 40X showing wispy collagen deposition. 
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 Figure 17: Myofibroblastic foci within an IPF lung. This H&E section cut from IPF paraffin-embedded 
lung shows a classical myofibroblastic foci. This area contains spindle-shaped myofibroblast cells with dispersed 
collagen deposition. 
Syndecan-1 and EC-SOD localization was determined by immunofluorescent staining of 
lung sections from normal human lung and sporadic IPF (Figure 18). Normal human lung in 
figure 18-a shows ubiquitous staining for EC-SOD (green) with sparce staining for syndecan-1 
(red) and colocalization of the two proteins (yellow, arrows). Similarly, in an area of normal lung 
architecture in an IPF lung section (Figure 18-c), EC-SOD staining is ubiquitous with sparse 
syndecan-1. In contrast, in areas of fibrosis in IPF lung, figure 18-b and d, syndecan-1 stains 
strongly on the abluminal surface of alveolar epithelial cells, terminal bronchiolar epithelial cells, 
and within areas of fibrosis (double asterisks) while EC-SOD staining decreases in fibrotic areas 
(single asterisk, Figure 18-b). Syndecan-1 and EC-SOD colocalize in some areas (Figure 18-d, 
arrows).  
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 Figure 18:Localization of EC-SOD and syndecan-1 in human lung sections. Green, EC-SOD; red, 
syndecan-1; blue, nuclear stain; yellow, co-localization. a) Normal human lung shows diffuse staining for EC-SOD 
in the lung parenchyma with focal areas of syndecan-1 expression that co-localize with EC-SOD (yellow; arrows). c) 
Areas of IPF lung with normal lung architecture show similar staining for both syndecan-1 and EC-SOD. In 
contrast, areas of fibrosis in IPF lung (b and d) show increased staining for syndecan-1 (red, asterisks) and decreased 
EC-SOD (green, single asterisk). e) Non-immune IgG staining control on control human lung.  
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In the asbestos mouse model, the injury leads to peribronchial and alveolar fibrosis 
similar to that seen in IPF and was confirmed by H&E staining in our pulmonary fibrosis model 
(Figure 19). Asbestos fibers can pierce and become embedded in the interstitium or engulfed by 
alveolar macrophages, as depicted in figure 19-d. To confirm the localization findings in human 
IPF lung, mouse lungs were stained for syndecan-1 and EC-SOD at 28 days post-exposure to 
TiO2 (control particulate) or asbestos. Normal lung from a wild type mouse treated with TiO2 
shows diffuse staining for EC-SOD (green) and sparse syndecan-1 (red) (Figure 20-a). In 
contrast, areas of fibrosis in figure 20-b show a decrease in interstitial EC-SOD (single asterisk), 
a diffuse increase in syndecan-1 (double asterisks), and co-localization of the two proteins in WT 
mice treated with asbestos (yellow, arrows). Likewise, EC-SOD KO mice show a significant 
increase in syndecan-1 in areas of fibrosis after asbestos exposure (Figure 20-d, double asterisk) 
compared to TiO2-treated mice (Figure 20-c). In summary, both the human and mouse lung 
staining show that syndecan-1 staining increases in areas of fibrosis with a decrease in interstitial 
EC-SOD.  
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 Figure 19: H&E staining of mouse lung after asbestos exposure. Paraffin blocks of WT mouse lung 
were sectioned (4μm) and stained with H&E. A) Normal mouse lung with thin alveoli and minimal inflammatory 
cells. B & C) Asbestos-treated mouse lung at 20X displaying interstitial fibrosi and inflammation. D) Higher 
magnification of the inset of C shows the presence of asbestos fibers surrounded by collagen and macrophages. 
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 Figure 20: Localization of EC-SOD and syndecan-1 in mouse lung sections. Green, EC-SOD; red, 
syndecan-1; blue, nuclear stain; yellow, co-localization. Lung sections from WT and EC-SOD KO mice treated with 
asbestos or TiO2 at 28 days post-exposure were stained for EC-SOD and syndecan-1. a) Normal lung architecture of 
TiO2-treated WT mice shows diffuse EC-SOD staining and focal syndecan-1 staining that co-localizes with EC-
SOD. b) Fibrotic areas of asbestos-treated WT mice show increased diffuse staining for syndecan-1 (double 
asterisks) that co-localize with EC-SOD (yellow, arrows). EC-SOD KO mouse lungs were stained for syndecan-1 
depicting c) normal lung architecture with TiO2 treatment and d) fibrosis with asbestos. There are significant 
increases in syndecan-1 staining in these fibrotic areas (double asterisk); e) H&E staining of normal lung 
architecture with TiO2 treatment shown in section c; f) No staining was seen with non-immune IgG control staining. 
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Previous studies report that during fibrotic injury, EC-SOD decreases in the lung 
interstitium while increasing in the alveolar space, as determined by western blot analysis of lung 
homogenates and BALF, respectively60, 63. Real time reverse transcriptase polymerase chain 
reaction (RT-PCR) was completed to confirm our IHC staining for EC-SOD in mouse lung. In 
wild type mice, asbestos exposure results in a significant decrease in EC-SOD gene expression 
(ddCT) at 14 days post-exposure (Figure 21A): percent relative EC-SOD gene expression from 
TiO2-treated lungs: 100% ± 4.96 versus 76.32% ± 3.40 for asbestos-treated lungs; *, p<0.05. 
Syndecan-1 gene expression in the lung is not significantly different between TiO2, control-
treated WT mice (100% ± 4.51) and EC-SOD KO mice (99.46% ± 4.51); p = 0.95. This led us 
to hypothesize that the absence of EC-SOD during pulmonary fibrosis, may leave 
syndecan-1 vulnerable to oxidative stress and lead to shedding of membrane syndecan-1. 
 
 
Figure 21: EC-SOD and syndecan-1 expression by Real time RT-PCR. Data are reported as percent 
relative ddCT gene expression for A) EC-SOD gene expression in WT mice treated with TiO2 or asbestos and B) 
syndecan-1 expression in control-treated WT and EC-SOD KO mice. *, p<0.05. 
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5.4 HEPARAN SULFATES & SYNDECAN-1 ARE OXIDATIVELY FRAGMENTED 
BY REACTIVE OXYGEN SPECIES. 
Asbestos injury to the lung results in increased production of reactive oxygen species (ROS) in 
the cell microenvironment of the lung. To mimic this production in an in vitro system, we 
utilized a CuSO4/H2O2 system, which generates superoxide and highly reactive hydroxyl 
radicals. To confirm that reactive oxygen species are produced in our CuSO4/H2O2 system, a 
colorometric assay was used to confirm superoxide production. Superoxide was significantly 
higher in reactions that contained both CuSO4 and H2O2 in the heparin system (Figure 22A). 
Similar ROS production was found in the heparan sulfate system (data not illustrated). Oxidative 
fragmentation of heparin and heparan sulfate in the ROS system was confirmed by gel 
electrophoresis followed by staining for polyanionic carbohydrate species with StainsAll. Both 
heparin and heparan sulfate were susceptible to oxidative fragmentation, as shown by a shift in 
the molecular weight bands of heparin or heparan sulfate to lower molecular weight species after 
ROS treatment (Figure 22B, blue boxes). 
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Figure 22: Superoxide production and fragmentation of heparin and heparan sulfate (HS). WST-1 
regeant was utilized to determine the relative amount of superoxide produced in the CuSO4/H2O2 reaction system. 
Optical density (O.D.) is proportional to superoxide production. A) Superoxide is produced in a Fenton-like 
reaction, which can be inhibited by EC-SOD. Similar superoxide levels were produced in the presence of HS as 
well. B) ROS production through the CuSO4/H2O2 reaction can fragment heparin (left lanes) and heparan sulfate 
(right lanes). ROS causes a band shift to lower molecular weight species (blue boxed areas). 
To determine if reactive oxygen species lead to shedding of syndecan-1 in vitro, A549 
cells were exposed to ROS in the presence or absence of human EC-SOD. Syndecan-1 can be 
oxidatively shed from A549 cells, as shown by a significant increase in levels of shed syndecan-
1 ectodomain in supernatants after ROS treatment (dot blot analysis, Figure 23 A and B). 
Syndecan-1 shedding was partially independent of protease activity because the shedding 
response was not completely abrogated by protease inhibitors for serine and cysteine proteases 
(DCI, Dichloro-isocoumarin and E-64, L-transepoxysuccinyl-leucylamido-[4-guanidino]butane) 
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and broad matrix metalloproteinases (GM2001 inhibitor). Furthermore, the presence of EC-SOD 
can significantly protect these cells from ROS-induced shedding of syndecan-1 ectodomains.  
Consistent with these findings, we fluorescently labeled syndecan-1 on cell monolayers 
and observed loss of cell surface syndecan-1 staining after ROS exposure and a recovery with 
the presence of EC-SOD. This confirms that shedding can occur oxidatively and can be inhibited 
by EC-SOD (Figure 23 C).  
 
Figure 23: EC-SOD protects against oxidative shedding of Syndecan-1. A549 cells were treated with 
ROS in the presence or absence of purified human EC-SOD. A & B) Dot blots of the culture medium were probed 
for human syndecan-1 ectodomain. Results are presented as fold increase in dot intensity over medium-treated 
controls (mean ± SEM). *,p<0.05. **,p<0.01. C) Representative images of fluorescent staining of syndecan-1 on 
A549 cells after ROS treatment in the presence or absence of EC-SOD (100 Units). 
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The concentration of syndecan-1 in A549 cell supernatant was quantified by ELISA for 
medium versus ROS treatment and were determined to be 9.2 ng/ml±2.3 and 42.3 ng/ml±1.9 
(p<0.0001), respectively. ROS treatment does not induce apoptosis in the cells, as there are no 
changes in caspase-3 activity in cell lysates after ROS treatment (caspase-3 activity, RFUs: 
medium 657.1 ± 73.1 versus ROS 405.3 ± 75.1; p = 0.073, n=3).  
5.5 OXIDATIVELY FRAGMENTED HS AND SYNDECAN-1 INDUCE 
NEUTROPHIL CHEMOTAXIS. 
Inflammatory cell influx is a feature of the pathogenesis of pulmonary fibrosis, both in IPF7, 9, 290 
and animal models57, 60, 62, 63, 226. The IPF patient population studied in this investigation had 
neutrophilia and eosinophilia in their BALF (Figure 12), as well as, increased levels of shed 
syndecan-1 (Figure 13 and 14). Because heparan sulfate (HS) and syndecan-1 have been shown 
to be important in IPF and animal models of pulmonary fibrosis, we hypothesize that oxidatively 
shed heparan sulfate and syndecan-1 would promote neutrophil chemotaxis in the lung. A 
modified Boyden chamber was used to evaluate the effect of EC-SOD and oxidatively 
fragmented heparin/HS or the shed syndecan-1 ectodomain on human neutrophil chemotaxis. 
Various amounts of ROS produced from CuSO4 and H2O2 could induce heparin/HS 
fragmentation and subsequent chemotaxis of neutrophils, specifically within the range of 0.8-2.0 
μM CuSO4 and 1.1–2.0 mM H2O2 (Figure 24). Neutrophil chemotaxis demonstrated increasing 
chemotaxis with higher concentrations of ROS, followed by a decrease with the highest 
concentration of ROS. All subsequent data presented are for concentrations of ROS produced by 
1.25 μM CuSO4 and 1.5 μM H2O2.  
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 Figure 24: Neutrophil chemotaxis is induced by ROS-fragmented heparin. Heparin was treated with 
ROS in the presence or absence of EC-SOD for 2 hrs then applied to the lower chamber of the chemotaxis assay. 
Data reported as neutrophil migration index. An index >1 represents positive chemotaxis. ROS significantly induced 
neutrophil chemotaxis and EC-SOD was capable of preventing this. *, p<0.05. 
ROS-treated heparin significantly (p<0.001) induces neutrophil chemotaxis compared to 
heparin without ROS (Figure 25A) and EC-SOD can inhibit this response (p<0.001). 
Unfragmented heparin does not induce chemotaxis. No significant differences were found 
between heparin without ROS and heparin with both ROS and EC-SOD. EC-SOD was able to 
inhibit chemotaxis at 50 Units (not illustrated) and 100 Units/lower well chamber by preventing 
superoxide from going to hydroxyl radicals and preventing heparin fragmentation and 
subsequent neutrophil chemotaxis. Similar results were found with ROS-fragmented heparan 
sulfate (HS) with inhibition of chemotaxis by EC-SOD (Figure 25 B). No chemotaxis was seen 
with ROS in the absence of heparin and heparan sulfate, nor with heparan sulfate proteoglycan 
(HSPG) alone. DMEM media, ROS and EC-SOD (100 Units) alone do not stimulate chemotaxis.  
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 Figure 25: EC-SOD inhibits neutrophil chemotaxis induced by oxidative fragmentation of heparin 
and HS. Chemotaxis was assessed using a modified Boyden chamber and ROS were produced using 1.25μM 
CuSO4 and 1.5mM H2O2. Purified EC-SOD significantly inhibits neutrophil chemotaxis induced by ROS-
fragmented (A) heparin *, p<0.001 and (B) heparan sulfate *, p<0.05 **, p<0.05 versus HS+ROS and 
HS+ROS+EC-SOD. Data are reported as mean cells number in the lower chamber ± SEM. 100 Units of EC-SOD 
was used and scavenges superoxide radicals to prevent further hydroxyl radical formation. 
The protection offered by EC-SOD can occur in two ways – through the superoxide 
scavenging activity or through direct binding to HS through the matrix-binding domain of EC-
SOD. To determine the mechanism through which EC-SOD inhibits HS oxidative fragmentation, 
EC-SOD and CuZnSOD were analyzed in the chemotaxis assay. CuZnSOD differs from EC-
SOD primarily from its lack of a matrix-binding domain. In the chemotaxis assay, human EC-
SOD (5-100 units) effectively prevents chemotaxis induced by HS and ROS. CuZnSOD is less 
effective in preventing chemotaxis at similar doses of SOD. CuZnSOD protection shows 
increases in protection at 5 and 100 units of SOD but less protection at 50 units. This 
phenomenon may be occurring due to molecular interactions in the cellular environment. ROS, 
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H2O2, EC-SOD and CuZnSOD alone do not induce chemotaxis (data not illustrated). This data 
suggests that EC-SOD prevents fragmentation of HSPG through both mechanisms: effective 
antioxidant activity and direct binding to HS through the matrix-binding domain. 
 
Figure 26: Antioxidant activity and direct binding of EC-SOD to heparan sulfate proteoglycan 
(HSPG) mediate inhibition of chemotaxis. The effect of EC-SOD binding with HSPG on the ability to fragment 
HS to cause neutrophil chemotaxis was assessed in a modified Boyden chamber. EC-SOD significantly inhibits 
chemotaxis induced by oxidatively fragmented HS at all concentrations used. CuZnSOD, which lacks the matrix-
binding domain partially inhibits chemotaxis. Data are reported as mean migration index ± SEM; * or **, p<0.05. 
Data from human IPF and in vivo mouse studies implicate shed syndecan-1 ectodomains 
in the pathogenesis of pulmonary fibrosis. To determine role of the syndecan-1 ectodomain in 
neutrophil chemotaxis, we applied a human syndecan-1 ectodomain (hS1ED) protein to the 
chemotaxis assay. The human S1ED is derived from a glutathione S-transferase fusion protein. 
The GST segment is proteolytically removed and the remainder is the syndecan-1 ectodomain of 
the core protein with no heparan sulfate side chains. hS1ED alone significantly (p<0.05) 
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increases chemotaxis of human neutrophils (Figure 27, HBSS 1.0 ± 0.49 versus hS1ED 4.42 ± 
0.83, p<0.005).  
 
Figure 27: Syndecan-1 ectodomain induces neutophil chemotaxis. Human syndecan-1 ectodomain 
(hS1ED) was analyzed in the chemotaxis assay at 1 μg/ml. Unmodified hS1ED promotes neutrophil chemotaxis 
(n=6, *,p<0.05). Data are reported as mean neutrophil migration index ± SEM. Data are representative of three 
separate experiments. 
Futhermore, supernatants from A549 cells containing syndecan-1 ectodomains shed by 
ROS are chemotactic to neutrophils (Figure 28B; migration index of ROS alone 1.70 ± 0.22 
versus HBSS control 1.00 ± 0.10, p<0.001). Knockdown of cell surface expression of syndcan-1 
and subsequent ROS treatment partially inhibits ROS-induced neutrophil chemotaxis (Figure 
28A and B; migration index of syndecan-1 siRNA with ROS 1.12 ± 0.07 versus ROS alone 1.70 
± 0.22, p<0.001). Therefore, the syndecan-1 ectodomain is oxidatively shed from the surface of 
cells during lung injury and is highly chemotactic to neutrophils. 
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Figure 28: Oxidatively shed syndecan-1 ectodomain induces neutrophil chemotaxis. Supernatants from 
A549 cells treated with medium, control siRNA or syndecan-1 siRNA for 24 hours prior to experimental treatment 
with HBSS or ROS, were analyzed in the chemotaxis assay. A) Knock down of syndecan-1 expression in A549 cells 
was achieved. 30μM Syndecan-1 siRNA was used for subsequent experiments. B) Oxidatively shed syndecan-1, in 
the supernatants from A549 cells, is chemotactic to neutrophils. Knockdown of syndecan-1 protein expression 
inhibits chemotaxis after ROS treatment. *, p<0.001 and **, p<0.01 versus HBSS; ^, p<0.001; n = 6. Grey bars: 
HBSS treatment; Black bars: ROS treatment. 
To evaluate the direct effect of EC-SOD on neutrophil chemotaxis and syndecan-1 
shedding in vivo, EC-SOD KO mice were co-treated with intratracheal asbestos and 50 units of 
purified human EC-SOD and evaluated at the 24-hour time point. EC-SOD significantly 
decreases the influx of neutrophils in the BALF (Fig. 29A percent BALF cells and 29B absolute 
cell numbers, *p<0.05). Furthermore, EC-SOD results in a significant decrease in shed 
syndecan-1 ectodomain levels in the BALF (Fig. 29C p<0.01). Human EC-SOD is detectable in 
the BALF of EC-SOD KO mice after 24 hours in both the TiO2 and asbestos groups co-treated 
with EC-SOD (Fig. 29D). However, asbestos injury causes clearance of EC-SOD. The amount of 
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EC-SOD present in the BALF of this group was much lower and required longer exposure times 
on western blot. 
 
Figure 29: Intratracheal instillation of EC-SOD decreases inflammation and prevents asbestos-
induced shedding of syndecan-1. EC-SOD KO mice were co-treated with purified human EC-SOD and asbestos or 
TiO2. BALF was collected after 24 hours. Co-treatment with EC-SOD and asbestos results in decreased neutrophils 
and decreased levels of shed syndecan-1 in the BALF after 24 hours.  (A) Percent cell type of inflammatory cells in 
BALF cytospins , *, p<0.001, **, p<0.05; (B) Absoute cell number of inflammatory cells in BALF cytospins. *, 
p<0.05, n=4; (C) BALF levels of shed syndecan-1, assessed by western blot, *, p<0.05, **, p<0.01; in the BALF, 
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n=4. (C) Human EC-SOD is present in the BALF of EC-SOD KO mice after 24 hours. Asbestos-injured mice show 
less retention of EC-SOD than TiO2 treated mice. Western blot exposure times are noted to the left. 
Heparin and heparan sulfate may interact with and signal through toll like receptors, 
TLR-4, and integrins, both of which are present on inflammatory cells. To investigate the 
mechanistic roles of TLR-4 and integrins in heparan sulfate mediated neutrophil chemotaxis, we 
utilized blocking antibodies against TLR-4 and integrins-β1 and β3 in the chemotaxis assay. 
Anti-TLR4 antibody prevents chemotaxis induced by oxidatively fragmented heparin (Figure 30, 
*, p<0.05). LPS induction of chemotaxis via TLR-4 was used as a positive control.  
 
Figure 30: Toll-like receptor 4 partially mediates neutrophil chemotaxis induced by fragmented 
heparin. Anti-TLR4 blocking antibody was incubated with human neutrophils for 30 minutes prior to addition to 
the chemotaxis assay. Anti-TLR4 antibody inhibits neutrophil chemotaxis induced by ROS-fragmented heparin. 
*,p<0.05. Data are reported as mean lower chamber cell count ± SEM. 
Incubation of neutrophils with a blocking antibody against integrin β1 prior to the 
chemotaxis assay, inhibits chemotaxis to oxidatively fragmented HSPG (Figure 31). An antibody 
against integrin β3 does not modulate chemotaxis. Species-specific IgG was used as a control for 
the blocking antibodies. 
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 Figure 31: Chemotaxis induced by oxidatively fragmented HS is mediated through Integrin-β1. 
Blocking antibodies to integrin-β1 or integrin-β3 were incubated with human neutrophils for 30 minutes prior to 
addition to the chemotaxis assay. Anti-integrin-β1, but not integrin-β3, inhibited neutrophil chemotaxis induced by 
oxidatively fragmented HSPG. Control IgG did not affect neutrophil chemotaxis. Data are reported as mean 
neutrophil migration index ± SEM. 
5.6 OXIDATIVELY FRAGMENTED SYNDECAN-1 INDUCES ABHERRENT 
EPITHELIAL WOUND HEALING. 
Alveolar epithelial cells are susceptible to injury and cell death in the lung. Re-epithelialization 
to restore areas of lost cells is critical for effective repair. Dysregulated re-epithelialization or 
wound healing is thought to be involved in the pathogenesis of pulmonary fibrosis29. Because 
syndecan-1 is thought to regulate cell adhesion, we hypothesize that shed syndecan-1 
ectodomains and the loss of cell surface syndecan-1 would alter wound healing in alveolar 
epithelial cells. To investigate this, we isolated and utilized primary mouse type I alveolar 
epithelial cells (AECs, Figure 32) in a wound healing “scratch” assay. Human S1ED, added at 
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the time of the wound, significantly inhibits re-epithelialization in primary mouse AECs after 20 
hours (Figure 33, percent healing ± SEM): medium alone, 65.0% ± 3.7 healing versus hS1ED, 
51.6% ± 1.7; *, p<0.05.  
 
Figure 32: Primary mouse alveolar epithelial cells - type I pneumocytes. A highly pure population of 
primary mouse AECs was achieved. Cytospun AECs stain positive for cytoplasmic mucin granules (dark blue dots) 
and in vitro form cell-cell connections in monolayers during culture (7 days after cell harvest).  
 
Figure 33: Human syndecan-1 ectodomain (hS1ED) inhibits re-epithelialization of primary mouse 
AECs. Primary AECs were grown on collagen IV, wounded and imaged at 4X magnification with phase 
microscopy at time 0 and 20 hours. *, p<0.05. Data is reported as precent wound healing (mean ± SEM), n=6/group.  
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The scratch assay was also completed using A549 cells (human alveolar epithelial cell 
line). Supernatants from A549 cells exposed to ROS inhibit re-epithelialization of A549 
monolayers after wounding and lead to a large decrease in cell adhesion after 20 hours (data not 
illustrated). hS1ED added at the time of wounding, also inhibits healing of A549 cells (Figure 
34): control, 92.4% ± 1.2 versus hS1ED (500 ng/ml) 73.5% ± 3.5; *, p<0.01. After treatment 
with hS1ED, both A549 cells and primary AECs display a rounded, less adhered morphology. 
Knockdown of syndecan-1 expression in A549 cells was achieved with siRNA to human 
syndecan-1 (80% knockdown 24 hours after siRNA treatment, Figure 28A). The loss of cell 
surface syndecan-1 expression, 24 hours post-transfection, results in a significant decrease in 
alveolar re-epithelialization (Figure 34): negative control siRNA 80.1% ± 6.6 versus syndecan-1 
siRNA 49.3% ± 5.7; *, p<0.001. The addition of hS1ED, immediately after wounding, to siRNA 
treated cells partially augments the impaired healing response, however, was not a statistically 
significant change. 
The previous chemotaxis data suggests that heparan sulfate proteoglycans, such as 
syndecan-1, are more chemotactic when the heparan sulfate glycosaminoglycan (GAG) side 
chains are oxidatively fragmented and removed. This would leave the core protein ectodomain 
without GAG chains, which we have shown can directly induce neutrophil chemotaxis and 
inhibit alveolar re-epithelialization. To confirm that the region of the protein ectodomain that 
contains the primary GAG attachment sites is a portion that inhibits wound healing, we created a 
20 amino acid long peptide from the human syndecan-1 N-terminal amino acid sequence. The 
peptide sequence with the serine-glycine GAG attachment sites is shown in figure 35A. This 
peptide significantly inhibits wound healing in primary AECs (Figure 35B). This suggests that 
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oxidatively shed syndecan-1 with modification of its GAG/heparan sulfate side chains can 
actively alter wound healing. 
 
Figure 34: Human syndecan-1 ectodomain (hS1ED) inhibits wound healing while cell surface 
syndecan-1 promotes re-epithelialization. A549 cells were cultured on collagen IV, wounded and treated with 
human S1ED. Phase images were taken at 0 and 18 hours. hS1ED inhibits wound healing in A549 cells. Knockdown 
of syndecan-1 expression with 30μM siRNA (siRNA treatment was given 24 hours prior to the wound) results in 
impaired wound healing or re-epithelialization and changes the cell morphology from a flat, squamous cell to a 
rounded cell. *, p<0.05; **, p<0.001 versus media and control siRNA. There was no difference between baseline 
wound healing with medium and control siRNA. Successful knock down with siRNA is shown in figure 28A. 
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 Figure 35: Syndecan-1 ectodomain peptide with GAG binding sites inhibits wound healing. A) A 
peptide composed of amino acids 11-30 of the syndecan-1 core protein ectodomain was synthesized. This region 
contains 2 of the 4 glycosaminoglycan (GAG) binding sites (serine-glycine repeats) within the ectodomain. B) This 
syndecan (syn) peptide inhibits wound healing in primary mouse AECs at 20 hours; *, p<0.05, n=6. 
Finally, we investigated the effect of asbestos fibers on re-epithelialization in primary 
mouse AECs in the scratch assay. Crocidolite asbestos fibers (9.5μg/well) were added 
immediately after wounding and significantly inhibits re-epithelialization of primary mouse 
AECs (Figure 36). Asbestos treatment caused a 20% reduction in wound healing by 24 hours and 
33% by 48 hours. Thus, asbestos not only induces cell death through the production of reactive 
oxygen species, but it impairs the normal wound repair process. 
 
Figure 36: Asbestos fibers impair re-epithelialization of primary AECs. Cells were cultured on 
collagen IV, wounded and treated with asbestos. Phase images were taken at 0, 24 and 48 hours to assess wound 
healing. *, p<0.05, n=6. 
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5.7 SYNDECAN-1 ECTODOMAIN INDUCES FIBROGENESIS. 
During wound repair, if epithelial cells fail to re-epithelialize the basement membrane of the 
alveolar surface, fibroblasts will proceed by proliferating and depositing extracellular matrix 
components such as collagen, creating fibrosis. To determine the effect shed hS1ED on 
fibroblasts, LL47 cells (human lung fibroblast cell line) were treated with 1 μg/ml human S1ED 
or mouse S1ED (mS1ED) for 24 or 48 hours and metabolically active cells were detected as 
described in the methods section. hS1ED and mS1ED significantly increase the proliferation of 
lung fibroblasts after 24 hours (Figure 37 A and B, p<0.01). Furthermore, hS1ED induces TGF-
β1 release from fibroblasts treated for 48 hours (Figure 38): TGF-β1– medium 0.34ng/ml ± 0.08 
versus hS1ED 0.80ng/ml ± 0.05; *, p<0.05. There was no detectable increase in active TGF-β1 
(data not shown). hS1ED does not lead to myofibroblast differentiation of fibroblasts, as 
determined by α-smooth muscle actin in cell lysates after treatment for 48 hours (western blot 
analysis - normalized net band intensity (α-SMA/β-actin): media 0.174 ± 0.031 versus hS1ED 
0.166 ± 0.026). 
 
Figure 37: Human and mouse syndecan-1 ectodomains increase human lung fibroblast proliferation. 
LL47 fibroblasts were treated with either human S1ED or mouse S1ED for 24 hours and cell proliferation was 
assayed. The absorbance at 490nm is proportional to the number of metabolically active cells. *p<0.01 n=8. 
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 Figure 38: Syndecan-1 ectodomain induces TGF-β1 bioavailability in human lung fibroblasts. LL47 
fibroblasts were treated for 48 hours with medium or human S1ED. Supernatants were subsequently assayed for 
total TGF-β1 (ng/ml). Data are reported as mean ± SEM, *, p<0.01. No differences in active TGF-β1 levels were 
detected, n=6. 
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6.0  DISCUSSION  - PULMONARY FIBROSIS 
Studies of pulmonary fibrosis have found that EC-SOD inhibits inflammation and fibrosis in 
lung injury models57, 63, 291. EC-SOD is lost from the interstitium from the lung and increases in 
the airspaces60, 292. This loss of EC-SOD may leave the extracellular matrix of the lung 
vulnerable to increases in oxidative stress, which is evident in idiopathic pulmonary fibrosis 
(IPF)11, 126, 176, 293. We hypothesized that one mechanism through which EC-SOD protects the 
lung from oxidant-induced damage, inflammation, and fibrosis is by preventing oxidative 
fragmentation of heparan sulfate (HS), specifically syndecans, in the extracellular matrix 
(ECM). 
Syndecans have various known functions in tissues including mediating cell adhesion and 
localizing cytokines and growth factors. They can be shed from the cell surface in both 
physiological and pathological states. MMPs, including MMP1, MMP2, MMP7 and MMP9, are 
various proteolytic enzymes that have been implicated in human IPF131, 132, 294. Previous studies 
have shown a role for proteolytic cleavage of syndecan-1 by matrilysin (MMP7) in a bleomycin 
lung injury model and that syndecan-1 can complex with the chemokine KC to mediate 
inflammation263. The role for oxidative shedding of syndecans and the effects of the shed 
ectodomains during injury remain unclear. In our investigations, we have found that heparan 
sulfate can be fragmented by reactive oxygen species produced in a Fenton-like CuSO4/H2O2 
system. In addition, the ectodomain of syndecan-1 can be oxidatively shed from alveolar 
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epithelial cells, which can be prevented by EC-SOD. This suggests that heparan sulfate and 
syndecans in the extracellular matrix are sensitive to oxidative stress.  
Oxidative shedding also occurs in vivo during pulmonary fibrosis. Heparan sulfate 
fragments can be detected in the bronchoalveolar lavage fluid (BALF) of wild type mice after a 
24-hour exposure to asbestos, which generates reactive oxygen species via structural transition 
metals. Furthermore, EC-SOD KO mice, which display increased levels of oxidative stress, have 
significantly more heparan sulfate in BALF during both the inflammatory phase (24 hours) and 
fibrotic phases (days 14 and 28) of asbestos-induced pulmonary fibrosis. We have identified 
these shed species to be syndecan-1 and syndecan-4, which are expressed on alveolar epithelial 
cells. EC-SOD KO mice have further increases in shed syndecan-1 and syndecan-4 ectodomains 
into the BALF at the inflammatory and fibrotic phases of the asbestos model and in a second 
bleomycin model of fibrosis. The significance of these findings is further supported by increases 
in these syndecans in the BALF of IPF patients. Syndecan-1 levels in IPF BALF samples are 
significantly elevated at all stages of IPF disease severity. These data provide novel evidence 
implicating a role for oxidative stress in degradation of the extracellular matrix of the lung, 
specifically syndecan-1 and -4. Previous studies have found that EC-SOD protein expression 
decreases in the lung interstitium with a corresponding increase in EC-SOD in the 
bronchoaloveolar lavage fluid (BALF). We found that EC-SOD decreases at the mRNA 
expression level during asbestos-induced fibrosis. The decrease in EC-SOD during pulmonary 
fibrosis and oxidative injury may be due to a loss of EC-SOD-producing epithelial cells in the 
lung interstitium. TGF-β, a growth factor important in fibrosis, has also been shown to down-
regulate EC-SOD expression216. Because EC-SOD binds to heparin species in the lung, HS 
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shedding may be one mechanism through which the distribution of EC-SOD changes with 
oxidative injury. 
While present in the BALF after injury, the functions of shed syndecan-1 during 
pulmonary fibrosis remain unknown. Inflammation and aberrant wound healing are key 
pathological processes involved in IPF and were thus investigated. Neutrophil influx into the 
lung during injury is a characteristic of human IPF and animal models of pulmonary fibrosis. 
Oxidatively fragmented heparan sulfate and the syndecan-1 ectodomain (as would be shed from 
the matrix) are highly chemotactic to neutrophils. Oxidative damage and removal of the 
carbohydrate side chains of HSPG can expose the syndecan core protein. The core protein is then 
able to induce chemotaxis. siRNA studies in A549 epithelial cells support the direct role of the 
syndecan-1 ectodomain in induction of chemotaxis. Shedding of syndecan-1 and subsequent 
neutrophil chemotaxis can be inhibited by EC-SOD in vivo and in vitro, highlighting one 
mechanism through which EC-SOD is mediating inflammation. Thus, our studies provide the 
first report of a novel mechanism by which oxidants induce shedding of the syndecan-1 
ectodomain, which can directly promote neutrophil chemotaxis in the absence of cytokines 
and chemokines.  
The mechanism through which shed syndecan-1 induces chemotaxis is unknown, but toll 
like receptor 4 (TLR-4) and integrin-β1 on neutrophils are likely involved based on our findings. 
TLR4 is known for its pathogen recognition of gram-negative bacteria. Excessive syndecan-1 
shedding may also be recognized by TLR-4 as a signal of tissue injury. Integrins are intricately 
involved in cell-cell and cell-matrix communication and adhesion. Integrins may also utilize 
membrane bound syndecans as co-receptors and shed syndecans as signals of injury to trigger 
cellular migration and the repair process. 
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Wound healing studies suggest that in addition to pro-inflammatory properties, shed 
syndecan-1 impairs alveolar re-epithelialization. Human syndecan-1 ectodomain (hS1ED) was 
found to inhibit wound healing of epithelial monolayers at physiological levels of syndecan-1. 
siRNA studies indicate that cell surface bound syndecan-1 is important in the normal repair 
process, as knockdown of syndecan-1 with siRNA technology results in significant impairment 
of wound healing. Subsequent studies with a synthesized syndecan-1 peptide suggest that the 
region of the syndecan-1 protein with GAG binding sites mediates this response. Other 
investigators report that syndecan-1 interacts with integrins to mediate cell adhesion and 
activation252, 258. In this study, shed syndecan-1 may be competitively binding with integrin 
subunits to inhibit re-epithelialization. Thus, during lung injury, syndecan-1 gains a pathologic 
function when it is oxidatively shed (neutrophil chemotaxis and inhibition of re-epithelialization) 
and losses it’s homeostatic function as a membrane bound protein, for the epithelium during the 
repair process (inhibition of re-epithelialization). 
The pathogenesis of IPF also involves fibroblasts and a potential dysregulation of their 
function. hS1ED promotes lung fibroblast proliferation and release of TGF-β1 from fibroblasts. 
This suggests that syndecan-1 may contribute to the pulmonary fibrosis by activating fibroblasts 
and the release of pro-fibrotic paracrine mediators like TGF-β1. This pro-fibrotic and anti-
inflammatory growth factor has also been shown to downregulate EC-SOD expression216, which 
would alter levels of oxidative stress in the lung. 
Tissue homogenate, immunofluorescent staining, and real time RT-PCR data indicate that 
syndecan-1 cell surface expression increases in areas of fibrosis while EC-SOD decreases in the 
lung after injury. IHC staining for syndecan-1 shows that the expression increases are unique to 
areas of active fibrosis because changes are not seen in areas with normal lung architecture. The 
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loss of interstitial EC-SOD during pulmonary fibrosis may increase the vulnerability of matrix 
proteins and heparan sulfate, including syndecan-1, to the increases in oxidative stress seen in 
human IPF and animal models of pulmonary fibrosis. The combination of the changes that occur 
in interstitial syndecan-1 and EC-SOD distribution may favor fibrogenesis by creating a cycle of 
sustained inflammatory cell recruitment, abnormal epithelial wound healing, and increased TGF-
β bioavailability (Figure 39). The novel findings of this investigation show that the loss of EC-
SOD in the lung leaves syndecan-1 vulnerable to oxidative stress and that oxidant-induced loss 
of cell surface syndecan-1 impairs re-epithelialization, induces inflammation, and promotes a 
fibrotic microenvironment in the lung. 
 
Figure 39: Summary of Oxidative Stress in the Lung. Oxidative injury to the lung can lead to loss of 
epithelial cells and shedding of syndecan-1. This shedding may create a damaging cycle of inflammatory cell 
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chemotaxis, abnormal re-epithelialization of alveolar epithelium, and increased TGF-β bioavailability that contribute 
to fibrosis in the lung. 
6.1 CLINICAL SIGNIFICANCE AND FUTURE DIRECTIONS 
A recent clinical study shows prognostic benefit for predicting early mortality in IPF by 
evaluating neutrophil burden in the BALF of patients7. Moreover, syndecan-1 shedding into 
BALF may provide additional clinically relevant information on inflammatory and fibrotic 
mediators in IPF and may be one way to follow disease presence, which is suggested by our 
findings of increases in syndecan-1 levels in BALF at all IPF disease severities. We are 
addressing this possibility in the samples from the IPF patient population we evaluated for these 
studies. Furthermore, data from our asbestos mouse model suggests that syndecan-1 levels do 
correlate with neutrophil burden of the BALF. Additional investigations are required to 
determine if serum or urine detection of the ectodomains is possible, as these would involve less 
invasive sampling prodedures. The present studies show that oxidatively shed syndecan-1 
promotes neutrophil chemotaxis, impairs alveolar re-epithelialization after injury, and promotes 
fibrobrogenesis. Therefore, oxidatively shed syndecan-1 may be one potential therapeutic target 
to control fibrosis progression in IPF lungs. Targeting of the shed syndecan-1 ectodomain with 
an antibody provides a potential way to aid in the clearance of the fragments and control fibrosis 
progression.  
Our data show that intratracheal instillation of human EC-SOD inhibits syndecan-1 
shedding and neutrophil influx into the lung of EC-SOD KO mice at 24 hours post-asbestos 
exposure. Western blot analysis of BALF and lung homogenate samples revealed the presence of 
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the administered human EC-SOD, however, at lower levels in asbestos treated mice. Further 
studies could be completed to study the pharmacokinetics of exogenously administered 
intratracheal EC-SOD during pulmonary injury. How long does full length human EC-SOD 
remains in the un-injured lung and how EC-SOD is being removed from the lung after an injury. 
Several mechanisms could be involved in EC-SOD clearance: removal of EC-SOD to the serum 
due to a “leaky” lung, removal by leukocytes and uptake by epithelial or other resident cells. 
With a greater understanding of the half-life of administered EC-SOD, future studies could 
include EC-SOD administration during the course of fibrotic injury to evaluate its role in the 
fibrosis phase (after approximately day 7). 
Important questions remain about the biology of EC-SOD including if and how it signals 
in cells. Syndecan-4 is known to signal through PKC and acts as a co-receptor for growth factors 
such as fibroblast growth factor. Syndecans may also have a similar role for EC-SOD and how 
cells detect extracellular levels of EC-SOD because they are in very close proximity to one 
another. We have shown that EC-SOD increases in response to oxidative injury suggesting that 
EC-SOD levels may be detected by cells. In addition, interactions of EC-SOD with syndecans 
may mediate signaling if another receptor is involved. HSPG binding is required for complete 
signaling of FGF through its receptor. If EC-SOD does signal, a similar interaction may be 
required. Another aspect of EC-SOD biology that is unclear is how EC-SOD is transported into 
and out of cells. Heparan sulfates/syndecans are important in the endocytosis of LDL in 
adipocytes. Because of the high binding affinity of EC-SOD to heparan sulfate species, HSPGs 
may be good candidates for mediating uptake or recycling of EC-SOD by cells. 
Our data shows EC-SOD and syndecan-1 distribution in the lung interstitium. Syndecan 
expression in pulmonary inflammatory cells during pulmonary fibrosis injury remains unclear. 
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Peritoneal macrophages do express syndecans247, 250. However, the expression of syndecans on 
neutrophils and alveolar macrophages within the lung is currently unknown. Syndecans on 
pulmonary inflammatory cells may be involved in docking EC-SOD to the surface of leukocytes 
that are producing large amounts of reactive oxygen species. Macrophage syndecan expression 
and shedding may be key factors in the regulation of cytokine/growth factor signals in the lung.  
While not the focus of the current study, syndecan-4 clearly has a role in oxidative injury 
in the lung. The ubiquitous expression of syndecan-4 suggests that it is also expressed on 
leukocytes and fibroblasts. The function of syndecan-4 in fibroblasts is thought to involve cell 
migration, however additional functions in inflammation and fibrosis remain unclear. Our data 
shows that syndecan-4 increases in the lavage fluid during pulmonary fibrosis however, no 
significant changes in the lung homogenates are seen. The shed syndecan-4 could be coming 
from recruited neutrophils or resident macrophages.  
While this study focused on syndecans, the heparan sulfate glypican family should be 
investigated to determine their interactions with EC-SOD, susceptibility to oxidative stress and 
how they may mediate pulmonary injury and repair. 
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7.0  RESULTS – CARDIAC FIBROSIS 
7.1 LACK OF EC-SOD MODULATES CARDIAC MORPHOLOGY. 
We hypothesized that EC-SOD protects the heart from oxidant-induced fibrosis and loss of 
function by mediating normal cardiac function, inflammation and preventing oxidative ECM 
shedding. The significance of a lack of EC-SOD in normal cardiac morphology and during 
oxidant injury and fibrosis was determined utilizing wild type (WT) and EC-SOD KO mice. 
Echocardiography was utilized to assess cardiac dimensions and function. Control EC-SOD KO 
mice have a significant decrease in left ventricular posterior wall thickness (LVPWT, mm) 
compared to control WT mice (Figure 40A and relative thickness 40B; data in Table 2) and a 
significant increase in intra-ventricular end diastolic dimension (LVEDD, Figure 39C, *p<0.05; 
data in Table 2). While significant changes occur in the morphology of the LV, EC-SOD KO 
mice appear to functionally compensate as they have similar cardiac function compared to 
control WT mice (Figure 41A percent fractional shortening; Figure 41B percent ejection 
fraction; *p<0.05). 
  107
  
Figure 40: Changes in left ventricular morphology are present in control EC-SOD KO mice and after 
doxorubicin treatment. Cardiac dimensions were collected using echocardiography. A) LV posterior wall 
thickness (LVPWT, mm), *, p<0.05 compared to WT control. B) Relative posterior wall thickness (LVPWT / 
LVEDD), *, p<0.05 compared to WT control. C) LV end diastolic dimension (LVEDD, mm), *, p<0.05. All data is 
reported as mean ± SEM. 
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Table 2: Anatomic and Functional Cardiac Data for Wild type and EC-SOD KO mice. 
 
7.2 LACK OF EC-SOD EXACERBATES LOSS OF CARDIAC FUNCTION.  
The functional significance of cardiovascular EC-SOD after oxidant injury was determined by 
utilizing WT and EC-SOD KO mice given a single intraperitoneal injection of control saline or 
doxorubicin, with echocardiography assessment on day 15. Exposure to doxorubicin causes a 
significant decrease in the posterior wall thickness of the left ventricle (LVPWT) in wild type 
mice by echocardiography (Figure 39A; Relative posterior wall thickness 40B). No additional 
decreases were seen in the LVPWT of doxorubicin-treated EC-SOD KO mice, however 
functional impairment was evident. EC-SOD KO mice have a significant decrease in myocardial 
fractional shortening (figure 41A, *p<0.05; data shown in table 2) and ejection fraction (figure 
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41B, *p<0.05; EC-SOD KO control 62.70% ±4.28; doxorubicin 38.06% ±3.94). Doxorubicin-
treated WT mice have a trend towards decreases in FS and EF but do not reach significance. 
Figure 41C shows representative images for wild type and EC-SOD KO groups, including H&E 
of a cardiac section, and B-mode and M-mode cardiac images from echocardiography. These 
functional findings suggest that the lack of EC-SOD exacerbates systolic (contractile) 
dysfunction associated with doxorubicin-induced left ventricular injury.  
Weight loss was used as a marker of overall health and injury status in the doxorubicin 
model. In both wild type and EC-SOD KO mice, doxorubicin treatment led to a significant 
decrease in body weight compared to control mice (p<0.05, Table 2 - percent weight change). 
Notably, EC-SOD KO mice lost significantly more weight (9.48%) compared to wild type mice 
after doxorubicin administration (*p<0.05, Table 2). 
In addition, the lack of EC-SOD results in oxidative damage to membrane proteins in 
cardiomyocytes. Carbonyl modifications on proteins were detected in the membrane fraction of 
left ventricle homogenates in control and doxorubicin-treated wild type and EC-SOD KO mice. 
The lack of EC-SOD causes a significant increase in carbonyl modifications to proteins in 
control EC-SOD KO mice (Figure 42). Furthermore, doxorubicin treatment causes a significant 
increase in carbonyl groups in wild type animals. No further increase was seen in dox-treated 
EC-SOD KO mice. This data suggests that doxorubicin is producing extracellular oxidative 
stress leading to modifications in membrane proteins and that EC-SOD protects against this 
oxidative stress.  
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 Figure 41: Lack of EC-SOD results in a significant decrease in cardiac function after doxorubicin. 
Cardiac function was determined by echocardiography. A) Percent fractional shortening in wild type and EC-SOD 
KO mice. *, p<0.05; n=7-8; B) Percent ejection fraction of the left ventricle *, p<0.05; n=7-8; C) Representative 
images for wild type and EC-SOD KO groups depicting 4μm H&E-stained cardiac section at 1.6X magnification 
and B- and M-mode images of the left ventricle from echocardiography, n=7-8. Methods section 3.4.1 and Figure 5. 
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 Figure 42: Lack of EC-SOD and doxorubicin treatment lead to increases in extracellular oxidative 
stress. An oxyblot kit was used to detect carbonyl group formation on proteins in the membrane fraction of LV 
homogenates. Samples were ran on western blot and the membrane was probed for derivatized carbonyl groups. A 
MWM of derivatized proteins (MWM) and a non-derivatized control sample (ND Control) were included. The Lack 
of EC-SOD and doxorubicin treatment cause increased carbonyl modifications in membrane proteins, *, p<0.05.  
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7.3 LACK OF EC-SOD RESULTS IN INCREASED FIBROSIS AFTER 
DOXORUBICIN. 
Lack of cardiac EC-SOD results in increased fibrosis in left ventricular tissue, as shown 
by increased Sirius red staining of collagen fibers (Figure 43 C,D versus A,B) and increased 
collagen via trichrome staining (Figure 44 C,D versus A,B; Blue staining of collagen fibers). 
Deposition of acellular collagen is present between cardiomyocytes within the left ventricle 
(Figure 44-E, blue staining of collagen fibers), as well as, typical cellular pathology caused by 
doxorubicin including cytoplasmic vacuolization (Figure 44-F and 44-E, black arrows). 
Doxorubicin exposure caused a significant increase in LV hydroxyproline in wild type mice 
(Figure 45, WT control 0.76±0.04 μg/mg LV tissue; WT doxorubicin 0.89±0.03 μg/mg, 
*p<0.05). EC-SOD KO mice treated with doxorubicin had a significant increase in 
hydroxyproline compared to controls (Figure 45, EC-SOD KO control: 0.80±0.02 μg/mg LV 
tissue; EC-SOD KO dox 1.0±0.04 μg/mg LV tissue, *p<0.05) and a significant increase 
compared to similarly treated wild type mice (WT dox: 0.89±0.03 μg/mg LV tissue; EC-SOD 
KO dox 1.0±0.04 μg/mg LV tissue, *p<0.05). Control WT and EC-SOD KO mice had similar 
hydroxyproline levels in mice 8 weeks of age. 
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 Figure 43: Sirius red staining for collagen fibers in LV tissue. Collagen fibers are stained orange/red by 
sirius red. EC-SOD KO mice have significantly more LV fibrosis after doxorubicin (D) compared to WT dox mice 
(C). Images are representative of staining from each group. 
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 Figure 44: Trichrome staining for collagen deposition in LV cardiac tissue. LV tissue sections were 
stained with Masson’s trichrome. Collagen fiberes stain blue, nuclei are dark brown and cell cytoplasms stain red. 
EC-SOD KO mice have extensive collagen deposition after doxorubicin treatment (D) compared to WT dox mice 
(C). E) Collagen deposition (blue staining) at higher magnification in the LV tissue of a doxorubicin-treated EC-
SOD KO mouse. F) Cellular ultra-structural pathology can be appreciated by cytoplasmic vaccuolization (arrows) in 
a cardiac section from a doxorubicin-treated EC-SOD KO mouse. These are also noted on section E with an arrow. 
  115
Wildtype EC-SOD KO
0.0
0.3
0.6
0.9
1.2
Control
Doxorubicin*
*
*
 
Figure 45: Hydroxyproline analysis of collagen content in LV tissue. EC-SOD KO mice develop 
significantly more fibrosis as assessed by hydroxyproline content after doxorubicin compared to WT dox mice. *, 
p<0.05 WT dox or KO dox compared to respective control mice; Bar with *, p<0.05 EC-SOD KO dox versus WT 
dox, n=6-8.  
7.4 LACK OF EC-SOD AND OXIDATIVE INJURY INCREASES SHEDDING OF 
SYNDECAN-1, MYOCARDIAL INFLAMMATION, AND APOPTOSIS. 
In wild type mice, doxorubicin exposure leads to an increase in total protein expression of EC-
SOD in LV tissue homogenates (Figure 46A). Proteolyzed EC-SOD increases in serum after 
doxorubicin (Figure 46B, p<0.05) while there is no change in EC-SOD mRNA expression by 
quantitative real time RT-PCR (Figure 46C, percent relative ddCT expression). Syndecan-1 is a 
major component of the extracellular matrix and anchors EC-SOD to cell surfaces. Serum levels 
of shed syndecan-1 increase in WT mice after doxorubicin and high serum levels are also seen in 
control EC-SOD KO mice with no further increase after doxorubicin (Figure 46D). In left 
ventricle homogenates, syndecan-1 membrane bound protein decreases after doxorubicin in both 
  116
WT and EC-SOD KO mice (Figure 46E) corresponding to the increase in serum syndecan-1 
levels. Syndecan-1 mRNA expression significantly decreases in EC-SOD KO mice after 
doxorubicin by day 15 (Figure 46F, p<0.05) but does not in WT mice. Inflammatory cell 
infiltration, shown by CD45-(+) cell staining in LV tissue, is evident in WT dox mice and is 
further enhanced with the lack of EC-SOD and dox treatment (Figure 47; red staining = CD45, 
blue = nuclei).  
Doxorubicin results in increased cell death shown by a trend in increased serum lactate 
dehydrogenase (LDH) (Figure 48A). Furthermore, WT and EC-SOD KO mice have significant 
decreases in total heart mass by day 15 after doxorubicin treatment (Table 2, *p<0.05). We 
determined if this decrease in heart mass was due to apoptotic cell death. The lack of EC-SOD 
results in increased apoptosis in the LV after oxidative injury, as evident by a significant increase 
in active caspase-3 in soluble heart homogenates after doxorubicin (Figure 48B, activated 
caspase-3, 12-17kDa form; KO control 0.11±0.02 ; KO dox 0.57±0.10, *p<0.05). The ratio of 
active to inactive caspase-3 is significantly higher in doxorubicin-treated EC-SOD KO mice 
compared to control KO mice and both WT treatment groups (Figure 48C, Caspase-3 ratio 
(active/inactive): EC-SOD KO control 0.11±0.01 and EC-SOD KO dox 0.64±0.13, *p<0.05; WT 
control 0.12±0.04; WT dox 0.19±0.05, *p<0.05 versus KO dox). There were no changes in the 
inactive pro-form of caspase-3 (Figure 48B, 37kDa) suggesting that there is an increase in 
caspase-3 activation with a lack of EC-SOD and doxorubicin treatment. By TUNEL analysis, the 
lack of EC-SOD further modulates the number of apoptotic cells in both control and 
doxorubicin-treated groups, as shown by the presence of TUNEL-positive cells (Figure 48C, 
TUNEL (red), DAPI nuclear stain (blue), overlay).  
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 Figure 46: Doxorubicin treatment cause alterations in antioxidant EC-SOD and syndecan-1 of the 
ECM. A) EC-SOD in left ventricular (LV) homogenates after doxorubicin-treatment.  Band intensity normalized to 
β-actin, mean ± SEM. *p<0.05 B) Serum EC-SOD after doxorubicin-treatment.  Band intensity normalized to 
ponceau red, *p<0.05.  C) Left ventricular EC-SOD mRNA expression after doxorubicin in wild-type mice, 
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presented as percent relative ddCT expression, mean ± SEM. n=4 D) Syndecan-1 ectodomains are shed from tissue 
into the serum due to doxorubicin-treatment and the lack of EC-SOD. Band intensity was normalized to ponceau 
red. E) Syndecan-1 in left ventricular (LV) homogenates after doxorubicin-treatment. Band intensity normalized to 
β-actin, mean ± SEM. F) Left ventricular syndecan-1 mRNA expression after doxorubicin in wild-type and EC-SOD 
KO mice, percent relative ddCT expression, normalized to endogenous GAPDH expression. *p<0.05. n=4. 
 
 
Figure 47: Lack of EC-SOD exacerbates inflammatory cell infiltration after oxidative injury due to 
doxorubicin.  LV tissue sections were fluorescently stained for CD45 (leukocyte marker) and DAPI nuclear stain 
and imaged by standard immunofluorescence. Red = CD45, Blue = nuclei. 
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 Figure 48: Lack of EC-SOD exacerbates apoptotic cell death in LV tissue. A) Serum lactate 
dehydrogenase (LDH) in serum from wild type and EC-SOD KO mice.  B) Caspase-3, Inactive (37kDa pro-form) 
and active (12-17kDa form), in the soluble protein fractions of LV homogenates. Grey bars: Control group, Black 
bars: Doxorubicin group. Normalized to coomassie blue staining. *p<0.05, n=3-5. C) Relative active caspase-3 
(active form to inactive form). *p<0.05.  D) Immunofluorescent TUNEL staining for DNA strand breaks in left 
ventricular tissue sections from each treatment group. Top panel: TUNEL (red staining), middle panel: DAPI 
nuclear stain (blue), bottom panel: overlay of TUNEL and DAPI. 
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8.0  DISCUSSION – CARDIAC FIBROSIS 
EC-SOD is an important antioxidant in the cardiovascular system for its protective role against 
oxidative stress mediated by superoxide and other free radicals197, 198. We hypothesized that EC-
SOD protects the heart from oxidant-induced fibrosis and loss of function by mediating 
normal cardiac function, inflammation and preventing oxidative shedding of the ECM.  
In this investigation, we found novel data supporting an important role for EC-SOD in 
cardiac morphology in the normal state, in addition to, protection against oxidative cardiac 
injury, including left ventricular (LV) fibrosis, inflammation, apoptosis, and loss of cardiac 
function. We utilized wild type and EC-SOD KO mice to evaluate the functional significance of 
a lack of EC-SOD in a baseline state and under oxidative stress. Doxorubicin-induced oxidant 
production138 and subsequent cardiac fibrosis was utilized as our injury model. 
Our data show that a lack of EC-SOD leads to changes in the morphology of the left 
ventricle including significant posterior wall thinning and increased LV end diastolic dimensions 
at baseline compared to age and gender matched control wild type (WT) mice (Figure 40). 
Interestingly, control EC-SOD KO mice do not have detectible functional impairment with these 
changes (Figure 41A, B) until they are challenged with an injury, such as oxidative stress via 
doxorubicin. In WT mice, doxorubicin causes a significant decrease in the LV posterior wall 
thickness (Figure 40A). In EC-SOD KO mice, doxorubicin does not cause an additional decrease 
in LVPWT however, it does cause a significant loss of cardiac function in the KO mice that does 
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not occur in the WT mice. This suggests that lack of EC-SOD exacerbates systolic dysfunction 
associated with doxorubicin cardio-toxicity. In addition, this suggests that EC-SOD is critical for 
maintaining a normal ventricular morphology and that the lack of EC-SOD increases sensitivity 
to oxidative stress and damage to the heart, which results in enhanced functional impairment. 
This is the first study examining the role of EC-SOD in maintaining cardiac morphology. EC-
SOD KO mice also had significant increases in oxidative carbonyl modifications in membrane 
proteins suggesting increased extracellular oxidative stress. Control treated EC-SOD KO mice 
appear to develop spontaneous cardiac fibrosis at baseline compared to control WT mice by 
Trichrome staining (data not shown). 
A primary pathological feature of doxorubicin cardio-toxicity is cardiac fibrosis that 
leads to non-ischemic dilated cardiomyopathy and congestive heart failure198. Our in vivo 
histological and biochemical data show that doxorubicin causes significantly more left 
ventricular (LV) fibrosis and collagen deposition in EC-SOD KO mice compared to wild type 
mice (Figure 42-44).  The pathological findings include remodeling of the LV myocardium 
through the deposition of collagen (Figure 43E) and the presence of cytoplasmic vacuolization 
(Figure 43F, black arrows), which together alter the functional capacity of the tissue. 
It has been reported that syndecan-1 may protect against ventricular dilation and 
dysfunction in ischemic cardiac injury255. Our studies in pulmonary fibrosis show that EC-SOD 
prevents oxidative shedding of syndecan-1 from the lung epithelium and that the syndecan-1 
ectodomain induces inflammation and may also contribute to pulmonary fibrosis278. Doxorubicin 
treatment results in increased shed syndecan-1 in the serum of wild type mice. EC-SOD KO 
mice have increased syndecan-1 shedding with control treatment and no further increase with 
doxorubicin (Figure 46). Furthermore, there are corresponding decreases in membrane bound 
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syndecan-1 in the LV of both WT and EC-SOD KO mice after doxorubicin treatment. EC-SOD 
KO mice also have significantly lower syndecan-1 mRNA expression after doxorubicin 
compared to WT mice (Figure 46). These findings suggest that the lack of EC-SOD and the 
increase in oxidative stress in EC-SOD KO mice leads to syndecan-1 shedding and decreases in 
tissue expression after injury. The lack of cardiac EC-SOD also results in enhanced 
inflammatory cell infiltration after doxorubicin oxidative injury (Figure 47), which may be due 
to the increases in syndecan-1 shedding. Our studies in the lung show that shed syndecan-1 
promotes inflammatory cell recruitment. This may be a mechanism involved in oxidant damage 
to the heart. These findings support a novel role for EC-SOD in protecting the cardiac 
extracellular matrix and regulating inflammation. In addition, the data show that the lack of EC-
SOD results in a loss of membrane-bound syndecan-1 and cardiac remodeling consistent with 
dilation, which correlates with other investigations showing that a lack of syndecan-1 in ischemic 
heart injury exacerbates ventricular dilation. Based on this prior study, we would predict that 
shedding of syndecan-1 in EC-SOD KO mice and doxorubicin-induced oxidative shedding 
would exacerbate cardiac remodeling, leading to thinning of the left ventricle and dilation. 
Furthermore, this suggests that administration of EC-SOD or an SOD-like compound in these 
settings would protect against the ventricular remodeling and subsequent loss in cardiac function.  
The doxorubicin-induced oxidative cardiac injury that is seen in both wild type and EC-
SOD KO mice leads to a loss in LV tissue mass. This injury involves apoptotic cell death. 
Doxorubicin-treated EC-SOD KO mice have a significant increase in apoptosis compared to 
doxorubicin-treated WT mice (Figure 48). EC-SOD KO mice have significantly more caspase-3 
activation compared to wild type mice after doxorubicin treatment (Figure 48B and C, increased 
ratio of active to inactive caspase-3). EC-SOD KO mice also have increased TUNEL staining in 
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both the control and doxorubicin treatment groups compared to wild type mice. This data 
suggests that, mechanistically, EC-SOD functions in regulating apoptosis after exposure to 
doxorubicin by limiting caspase-3 activation. Moreover, EC-SOD protects against 
cardiomyocyte cell death, replacement of LV tissue with collagen, and subsequent loss of cardiac 
function, in part, by regulating oxidant-induced apoptosis. To investigate the interactions 
involved between the scavenging of extracellular superoxide by EC-SOD and intracellular 
apoptosis signaling, cardiomyocytes could be treated with a superoxide generating system. 
Apoptosis could be evaluated by caspase activation in cell lysates. If the addition of EC-SOD 
prevented apoptosis induction, this would suggest that superoxide mediates the signaling. If 
exogenous EC-SOD does not alter apoptosis induction, catalase should be utilized to determine if 
membrane-permeable H2O2 is mediating apoptotic signaling. 
The pharmacological activity of doxorubicin has 2 levels: first doxorubicin enters into 
cells to bind with DNA causing cellular dysregulation and second, it can undergo quinone-
semiquinone reduction-oxidation reactions to produce reactive oxygen species. Studies suggest 
that doxorubicin can generate intracellular and extracellular oxidants. The current findings that 
EC-SOD has such profound effects on the injury caused by doxorubicin are novel in the 
pathogenesis of doxorubicin-induced injury. Several mechanisms may explain these findings. 
EC-SOD may be preventing inflammation and fibrosis in the heart by protecting the ECM, 
specifically syndecan-1, on cardiac cells from oxidants. Shed syndecan-1 may be promoting 
leukocyte recruitment. Our pulmonary fibrosis studies confirm that the shed syndecan-1 
ectodomain is chemotactic to leukocytes. The loss of membrane bound syndecan-1 could then 
promote dilation of the left ventricle. In addition, our findings suggest that EC-SOD regulates 
  124
apoptosis by limiting caspase-3 activation. Increased apoptosis of LV cardiomyocytes can lead to 
LV wall thinning, ventricle dilation and loss of cardiac function. 
 
8.1 CLINICAL SIGNIFICANCE AND FUTURE DIRECTIONS 
This data highlights the implications of a lack of EC-SOD in the heart, which has a 
relevant clinical correlate. An EC-SOD gene variant has been implicated in increased risk for 
cardiovascular and ischemic heart disease. Studies report that an amino acid modification, EC-
SODR213G arginine-213 to glycine substitution, in the matrix-binding domain of EC-SOD results 
in decreased binding affinity of EC-SOD for the tissue matrix208, 210. Individuals with this 
mutation have increased serum levels of EC-SOD209, 211. Population studies suggest that 2-6% of 
individuals may carry this mutation, thus it is considered to be a common gene variant211, 212. A 
study from Denmark reports a 2.3 fold increase in the risk of ischemic heart disease in 
heterozygous individuals for EC-SODR213G 213. Our present data suggest that EC-SOD is 
  125
effective in protecting the heart against oxidant-induced cardiac fibrosis, LV posterior wall 
thinning and dilation, cardiomyocyte apoptosis, and loss of function. These findings raise 
interesting questions about the potential effects of the EC-SODR213G gene variant on an 
individual’s susceptibility to oxidative insults to the heart and further developing fibrosis and 
loss of cardiac function. 
This study shows that EC-SOD is important in the maintenance of normal cardiac 
morphology, the development of cardiac fibrosis, inflammation, and the loss of function 
associated with oxidative injury, as modeled by doxorubicin. These findings warrant additional 
studies on the utilization of antioxidants, potentially EC-SOD, for the prevention of oxidant-
induced cardiac injury. We are currently completing a study analyzing the efficacy of a 
superoxide dismutase-like agent, AEOL10150. This compound is a small porphyrin antioxidant 
analog and has been successful in limiting NF-kB activation and lipid peroxidation in 
hemorrhagic lung injury in mice227, protected against oxidative stress and apoptosis297, reducing 
infarct size by 43% in a brain ischemia model of middle cerebral artery occlusion298, and 
oxidative neurotoxicity299. WT and EC-SOD KO mice will be treated with saline or doxorubicin 
on day 0, as in prior experiments, with administration of AEOL10150 or vehicle twice daily for 
15 days. Cardiac function will be evaluated by echocardiography and cardiac fibrosis will be 
assessed by hydroxyproline. We hypothesize that AEOL10150 will decrease fibrosis and 
improve cardiac function in both WT and EC-SOD KO mice treated with doxorubicin.  
We are also completing aging studies in EC-SOD KO mice to evaluate their cardiac 
morphology and function compared to similarly aged WT mice. We have evaluated 5 week old, 
9 week old and 5 month old, untreated WT and EC-SOD KO mice. Our initial study shows that 
WT mice lose some cardiac function with age (percent ejection fraction and fractional shortening 
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of the LV). Interestingly, EC-SOD KO mice appear to lose cardiac function in a more drastic 
manner and earlier. Furthermore, EC-SOD KO mice have evident cardiac fibrosis already by 6 
weeks of age, which would predict progressed with age. A lack of EC-SOD has surprising 
effects on the heart and additional studies should be done to evaluate how EC-SOD protects the 
heart. Our current studies suggest that regulation of caspase activation and protecting the 
extracellular matrix are important functions of EC-SOD. The lack of EC-SOD may also be 
leading to uncoupling of NOS enzymes, such as eNOS. The uncoupling of eNOS would lead to 
increased superoxide production and a decrease in NO production, which has cardiovascular 
benefits when present. 
In our pulmonary fibrosis studies, we show that EC-SOD protects syndecan-1 from 
oxidative fragmentation and that the shed ectodomain of syndecan-1 promotes abnormal wound 
healing and fibrosis. The effect of the syndecan-1 ectodomain could be investigated in cardiac 
cell models including cardiomyocytes and cardiac fibroblasts. Structurally, syndecans are linked 
to the actin cytoskeleton, thus, disruption of membrane bound syndecan-1 could alter the 
contractile ability of cardiomyocytes. We are currently completing studies to determine 
syndecan-1 is shed proteolytically or oxidatively from neonatal rat cardiomyocytes. 
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9.0  FINAL DISCUSSION 
Tissue fibrosis of the lung and heart are thought to involve oxidant and anti-oxidant 
imbalances. The current literature on the pathogenesis of tissue fibrosis focuses primarily on the 
roles of epithelial, mesenchymal and inflammatory cells. The importance of oxidative 
modifications to the extracellular matrix and how this alters cellular reponses remains an open 
and under-investigated area. Specifically, the role for oxidative shedding of syndecans and the 
effects of the shed ectodomains during tissue injury remain unclear. Extracellular superoxide 
dismutase (EC-SOD) is the most abundant antioxidant in the extracellular space of many tissues 
where it is localized through binding to matrix components such as heparan sulfates, or 
syndecans. We provide novel evidence that oxidative shedding of syndecan-1 occurs in multiple 
organ systems and that EC-SOD has a primary role in protecting the matrix and down-stream 
consequences. While there are unique differences found in EC-SOD and syndecan-1 biology 
between the lungs and cardiovascular system during fibrosis, as discussed in previous sections, 
several novel biological themes over-arch the pathogenesis of inflammation and fibrosis.  
First, EC-SOD is a key anti-oxidant enzyme that protects the extracellular matrix of a 
tissue from increases in oxidative stress. We have shown that a lack of EC-SOD results in 
increased syndecan-1 shedding from the epithelium of the lung and into the serum, potentially 
from the endothelium of the vasculature. While tissue proteases are critical to tissue remodeling 
and the repair process, oxidative stress plays an important role. Potential therapeutic targets that 
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may be of use in controling fibrogenesis include utilizing antioxidants to modulate the oxidative 
stress levels in a tissue, as well as, matrix fragments may have negative effects within the cellular 
microenvironment. 
Second, syndecan-1 gains a pathological function when shed from the cell surface. Our 
data provides novel evidence that the shed syndecan-1 ectodomain is chemotactic to neutrophils, 
which is independent of chemokines, and impairs epithelial wound healing. Shed syndecan-1 
also gains a pro-fibrotic functions through its ability to induce proliferation of both lung and 
cardiac fibroblasts and to stimulate TGF-β release from lung fibroblasts. These findings suggest 
that shed syndecan-1 has a pathologic gain of function during the inflammatory and fibrotic 
phasis of fibrosis development.  
Finally, membrane-bound syndecan-1 functions by mediating cell-cell and cell-matrix 
adhesion, as well as, regulating growth factor and cytokine gradients and receptor activation. Our 
data suggests that when syndecan-1 is oxidative shed and lost from the epithelial cell surface, 
there is a loss of function that occurs. Epithelial wound healing is dysregulated and inhibited 
when membrane-bound syndecan-1 is lost. Therefore, oxidatively shed syndecan-1 may promote 
a fibrotic path for a tissue due to the loss of membrane-bound syndecan-1 during the initial 
injury. Without the appropriate re-epithelialization repair response, the cells are driven toward 
matrix deposition and fibrosis. 
In summary, the extracellular matrix creates a complex and critical microenvironment for 
the cells that make up a tissue. The pulmonary and cardiovascular systems are constantly 
challenged by oxidative insults that require well-coordinated repair responses. Extracellular 
superoxide dismutase is the primary antioxidant enzyme that protects this microenvironment. 
Through our studies of the pulmonary and cardiac fibrosis show that EC-SOD has a role in 
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maintaining the appropriate repair response. Oxidative stress, in addition to proteolytic 
fragmentation, leads to shedding of the extracellular matrix. Syndecan-1, which binds EC-SOD, 
is one of the affected matrix components. The loss of syndecan-1 from the cell surface leads to 
de-localization of EC-SOD, which promotes additional oxidative stress. The function of shed 
matrix components is unclear but important in aiding the understanding how to modulate disease 
development and progression. The syndecan-1 ectodomain gains pathological functions 
including leukocyte recruitment, pro-fibrotic actions such as the induction of fibroblast 
proliferation and TGF- bioavailability, and inhibiting re-epithelialization. Each of these 
functions, which appear to be conserved among cell types in various tissues, push a tissue away 
from normal wound healing toward fibrosis development. 
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Univ. of Pittsburgh - Medical Scientist 
Training Program (MSTP) 
Applicant Screening Committee 2009-2010 
 Student Interviewer Interdisciplinary Biomedical 
Program 
2008-2009 
 Student Committee Chair 
Student Guidebook Chair 
2007-2008 
 Second Look Applicant Weekend Planning Committee Spring 
2007 
 Student Mentoring Co-Chair 2006-2007 
 Annual Retreat Coordinator 2005-2006 
Bach Choir of Pittsburgh 
www.bachchoirpittsburgh.org 
Choir member, (80 members by audition) 2008-2009 
Honor Council - Univ. of Pittsburgh 
School of Medicine 
Student Representative   
- Class of 2008 & MSTP 
2004-
current 
 Academic Hearing Board Member 
-Formal Student Solicitor/Case Representative (Dean of 
Student Affairs-selected representative) 
2006 
(Informal) 
2007 
(Formal) 
Univ. of Pittsburgh School of Medicine Interviewer for the SOM Guaranteed Admit Program  Spring 
2009 
American Physician Scientists Assoc. Institutional Representative 
Membership Committee member 
2008-2009 
Duke Univ. Hyperbaric Research Center Guest Speaker–“Asbestos Model of Pulmonary 
Fibrosis” 
Feb. 12, 
2007 
Dept. of Pathology – Univ. of Pittsburgh 
Department Retreat Planning Committee 
Student Representative 2007-
current 
Dept. of Pathology – Annual Retreat Dept. of Pathology Graduate Student Top Poster Award 
Winner 
May 2008 
 Student speaker during oral research session. June 2007 
 Retreat Committee Member 2007 
Biomedical Graduate Student Association Secretary 2006-2007 
 Symposium Planning Committee 2007 
American Medical Students Association 
(AMSA) 
National Officer – Region 3 Associate Trustee 2005-2006 
 Co-President, Univ. of Pittsburgh  Chapter 
Community & Public Health Committee Chair 
2005-2006 
 National Conference Credentials Committee 2005 
Pittsburgh Women’s Abuse Shelter Medical Student Volunteer 2004-2005 
University of Nebraska (UNL) Honors 
Program 
Honors Thesis Research – Biology & Biochemistry Sept. 2000 
– May 2004 
Honors Program Ambassador Secretary 2002-2003 
UNL Mortar Board Senior Honors 
Society 
Class Induction Chairperson 2003-2004 
NU MEDS – Pre-medicine Group President 2002-2003 
- 4 year member Treasurer/ Consult 2003-2004 
National Society of Collegiate Scholars Vice Pres. of Community Service 2003-2004 
  
Medical and Science Memberships:
American Society of 
Investigational Pathology 
Member 2007-present 
Society for Free Radical 
Biology and Medicine 
Member, Student member of the 
Women in Science Group 
2006-present 
American Medical 
Association 
Member 2006-present 
American Medical 
Students Association 
Member 2004-present 
Pennsylvania Medical 
Society 
Member 2004-present 
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Myllärniemi, M, Lindholm, P, Ryynänen, M,  Kliment, C, Salmenkivi, K, Keski-Oja, J, Kinnula, 
V, Oury , T, Koli, K., "Gremlin-mediated decrease in BMP signaling promotes 
pulmonary fibrosis", Am J Respir Crit Care Med. 2008 Feb 1;177(3):321-9. PMID: 
17975199 
 
Carraway, MS,  Suliman, HB, Kliment, CR, Oury, TD, Welty-Wolf, KE, Piantadosi, CA.  
“Mitochondrial Biogenesis in the Pulmonary Vasculature during Inhalational Lung Injury 
and Fibrosis”, Antioxid Redox Signal. 2008 Feb;10(2):269-75.  PMID: 17999632 
 
Zheng M., Ramsay, A., Robichaux, M., Norris, K., Kliment, C., Crowe, C., Rapaka, R., Steele, 
C., McAllister, F., Shellito, J., Marrero, L., Schwarzenberger, P., Zhong, Q., Kolls, J., 
“CD4+ T cell–independent DNA vaccination against opportunistic infections,” J. Clin. 
Invest., 2005 Dec 1;115(12):3536-3544. 
 
Abstract Publications and Conference Presentations: 
  154
1. Kliment, CR, Gochuico, B, Piganelli, J, Rosas, I, Oury, T. Contrasts Between IPF and 
Mouse Models of Pulmonary Fibrosis. Am J of Resp. Crit. Care Med, April 2000; 179: 
A2716. Abstract (poster discussion session). 
2. Kliment, CR, Englert, J, Yu, G., Rosas, I, Oury, T. Oxidative Stress and EC-SOD Alter 
Syndecan-1 Distribution in Lungs with Pulmonary Fibrosis. Am J of Resp. Crit. Care 
Med, April 2009; 179: A3022. Abstract. 
3. Kliment, CR, Tobolewski, JM, McGaffen, KR, McTiernan, CF, Oury, TD. Lack of 
Extracellular Superoxide Dismutase leads to increased Doxorubicin-induced Cardiac 
Injury. American Heart Association Fellow Research Day, Pittsburgh, PA February 2009, 
Abstract. 
4. Kliment, CR, Englert, J, Yu, G., Rosas, I, Oury, T. Lack of EC-SOD leads to syndecan 
shedding in pulmonary fibrosis. FRBM, 45(1): S47.  Abstract (Oral presentation)  
5. Kliment, CR, Tobolewski, JM, McGaffen, KR, McTiernan, CF, Oury, TD. Lack of 
Extracellular Superoxide Dismutase leads to increased Doxorubicin-induced Cardiac 
Injury. FRBM, 45(1): S86. Abstract 
6. Kliment, CR, Englert, J, Yu, G., Rosas, I, Oury, T. Lack of EC-SOD leads to syndecan 
shedding in pulmonary fibrosis. 15th International Colloquium on Lung and Airway 
Fibrosis, Sunset Beach, NC, September, 2008. Abstract 
7. Kliment, CR, Englert, J, Yu, G., Rosas, I, Oury, T. Lack of EC-SOD leads to syndecan 
shedding in pulmonary fibrosis. University of Pittsburgh Department of Pathology 
Annual Retreat, May 2008, and Medical Scientist Training Program Annual Retreat, 
August 2008. Abstract 
8. Kliment, CR, Rosas, I, Oury, TD.  The Role of Heparan Sulfate, Oxidants, and 
Antioxidant EC-SOD in Pulmonary Fibrosis- Lack of EC-SOD  leads to Syndecan 
shedding.  Am J of Resp. Crit. Care Med, 2008 April; 177: A470. Abstract 
9. Kliment, CR, Tobolewski, J, Oury, T. Heparin/Heparan sulfate and EC-SOD 
Interactions in Pulmonary Fibrosis. FRBM , 2007 Nov.; 43(1):S111. Abstract 
10. Kliment, CR, Tobolewski, J, Oury, T. Heparin/Heparan sulfate and EC-SOD 
Interactions in Pulmonary Fibrosis. MD/PhD National Conference, Keystone, CO, July 
25-28, 2007. Abstract 
11. Kliment, CR, Tobolewski, J, Oury, T. Heparin/Heparan sulfate and EC-SOD 
Interactions in Pulmonary Fibrosis. Annual Pathology Department Retreat – Poster and 
oral presentation, Pittsburgh, PA, June 1, 2007. Abstract 
12. Kliment, CR, Tobolewski, J, Oury, T. Heparin/Heparan sulfate and EC-SOD 
Interactions in Pulmonary Fibrosis. Keystone International Symposium – Molecular 
Mechanisms of Fibrosis Meeting, Tahoe City, CA, March 11-14, 2007. Abstract 
13.  Kliment, CR, Tobolewski, J, Oury, T. Heparin/Heparan sulfate and EC-SOD 
Interactions in Pulmonary Fibrosis. Annual Pathology Research Day, University of 
Pittsburgh, November 2006 and 2007. Abstract 
14. Kliment, C.R., Romberger, D.J., Wyatt, T. Modulation of Airway Epithelial Cell 
Cytokine Release by Hog Barn Dust and Cigarette Smoke. American Thoracic Society 
(ATS) International Conference, Seattle, WA - May 2003, American Journal of 
Respiratory and Critical Care Medicine, Vol. 167, No. 7: p.A717. Abstract 
15. Kliment, C.R., Pardy, R.L.  Analysis of the Biological Effects of Algal 
Lipopolysaccharide on Human Whole Blood. Nebraska Academy of Science Annual 
Meeting, April 25, 2003, Programs and Proceedings 2003: p.41. Abstract 
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16. Kliment, C.R., Pardy, R.L.  Analysis of the Biological Effects of Algal 
Lipopolysaccharide on Human Whole Blood. 17th Annual National Conference for 
Undergraduate Research, University of Utah, March 13-15, 2003, Abstract Book: p.249. 
Abstract 
17. Kliment, C.R., Romberger, D.J., Wyatt, T. Modulation of Airway Epithelial Cell 
Cytokine Release by Hog Barn Dust and Cigarette Smoke. University of Nebraska 
Undergraduate Creativity and Research Experience (UCARE) Poster Symposium, 
October 2002. Abstract 
18. Kliment, C.R., Romberger, D.J., Wyatt, T. Immunosuppressant Drugs Block IL-6 and 
IL-8 Release in Airway Epithelial Cells Exposed To Dust Extracts From Swine 
Confinement Facilities. American Thoracic Society (ATS) International Conference, 
Atlanta, GA - May 2002, American Journal of Respiratory and Critical Care Medicine, 
Vol. 165, No. 8: p.A525. Abstract 
19. Kliment, C.R., Pardy, R.L.  The Biological Activity of Novel aLPS Assessed in Mouse 
and Human Macrophages.  International Endotoxin Society, 7th Conference, Abstract 
2002 
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and Human Macrophages.  Nebraska Academy of Science Annual Meeting, April 26, 
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IL-8 Release in Airway Epithelial Cells Exposed To Dust Extracts From Swine 
Confinement. University of Nebraska Undergraduate Creativity and Research Experience 
(UCARE) Poster Symposium, October 2001. 
 
